2004 İngilizce (in English)

Transcription

PUBLISHED BY THE TURKISH SOCIETY OF NEPHROLOGY
REGISTRY OF THE NEPHROLOGY,
DIALYSIS
AND
TRANSPLANTATION IN TURKEY
REGISTRY 2004
Central Registry Committee
Ekrem EREK
Kamil SERDENGEÇTİ
Chairman
President of Turkish Society of
Nephrology
Gültekin SÜLEYMANLAR
General Secretary of Turkish Society
of Nephrology
İstanbul - 2005
PUBLISHED BY THE TURKISH SOCIETY OF NEPHROLOGY
Important Note
All copyrights are reserved for Turkish Society of Nephrology.
Articles and figures might not be published without reference.
Contents and Design: OMEGA Contract Research Organization
Printing: Art Ofset
Printing date: June 2005
INTRODUCTION
15 Years in Turkish Nephrology Registry
Nephrology, Dialysis and Transplantation studies which are started in 1989 including solely Istanbul, are being
performed in country wide since 1990 and published by Turkish Society of Nephrology, annually
(except 1994). On the following two pages, you might see the names of the books and people who have worked
throughout the publishing process.
Till 1993 a lot of friends of us have taken place in Central Registry Committee. I am grateful to them.
For efforts they spent in communicating with foreign and domestic nephrology centers and for supports in
evaluating and commenting the collected data, I especially thankful to Kamil Serdengeçti, President of Turkish
Society of Nephrology and to Gültekin Süleymanlar, General Secretary, who are the indispensable and
permanent names of our society.
Mehmet Rıza Altıparmak and Nurhan Seyahi, two young assistant members of Central Registry Committee
have spent too much effort. Many thanks to them and to Lale Sever who has given her best support in
evaluation of pediatric nephrology results.
Registry studies which were performed with an amateur spirit till three years ago, are being executed by a
professional company since 2002, under control, support and audition of our Central Registry Committee.
You might see the graphics showing the now and then of the Turkish Registry for a period of 15 years.
In recent years, Turkish Nephrology Registry has started to take place in two big registries as a result of
contribution established with ERA-EDTA and USRDS.
For the support they gave to Turkish Nephrology Registry, we are grateful to Kitty Jager, Director of the ERAEDTA Nephrology Center and to Allan J. Collins, Director of the USRDS Coordinating Center. You might also
find the figures of this two big registries and comparative graphics by USRDS, including Turkish results.
Turkish Registry of 2004 is completed again with the extreme supports of the responsible persons of
nephrology, dialysis and transplantation centers. We stated the names of both them and the centers at the back
pages of this book. By this means we voice our gratitudes to them.
We are also grateful to managers and the staff of Omega Contract Research Organization who have collected
the data under the control and support of our Central Registry Committee and prepared the analysis report, and
to Fresenius Medical Care, the company that has yet once more sponsored the printing of this book.
June 2005, Cerrahpaşa, Istanbul
Prof. Dr. Ekrem EREK
Turkish Society of Nephrology, Chairman to Central Registry Committee
Registry of the Nephrology, Dialysis and Transplantation in Turkey, 2004
i
TURKISH SOCIETY OF NEPHROLOGY
REGISTRY GENERAL COMMITTEE
General Coordinator:
Prof. Dr. Kamil SERDENGEÇTİ
President of Turkish Society of Nephrology
EDTA-ERA Registry Coordinator for Turkey
Assistant Coordinator:
Prof. Dr. Gültekin SÜLEYMANLAR
General Secretary of Turkish Society of Nephrology
Assistant Members to Central Registry Committee:
Assoc. Prof. Mehmet Rıza ALTIPARMAK, Dr. Nurhan SEYAHİ
Coordinator for Pediatric Nephrology:
Prof. Dr. Lale SEVER
Regional Coordinators for Ankara and Mid-Turkey:
Şali ÇAĞLAR, Mehmet HABERAL, Enver HASANOĞLU, Şükrü SİNDEL, Neval DUMAN,
Ayşın BAKKALOĞLU, Oğuz SÖYLEMEZOĞLU, Ayşe ÖNER, Haluk KİPER, Cengiz UTAŞ,
Süleyman TÜRK, Necmettin GÜVENCE
Regional Coordinators for Istanbul and Thrace Region:
Emel AKOĞLU, Mehmet SEVER, Rezzan ATAMAN, Mine BESLER, Funda TÜRKMEN,
Uluğ ELDEGEZ, Muzaffer SARIYAR, Saniye ŞEN, Metin ERMAN, Nedim SARSMAZ
Hülya Karadayı ERGİN
Regional Coordinators for Bursa and Marmara Region:
Mustafa YURTKURAN, Kamil DİLEK, Mustafa GÜLLÜLÜ, Nilay OKTAY, Betül KALENDER
Regional Coordinators for Izmir and Aegean Region:
Ali BAŞÇI, Sevgi MİR, Taner ÇAMSARI, Fehmi AKÇİÇEK
Cüneyt HOŞCOŞKUN, Adam USLU
Regional Coordinators for Black Sea Region:
Tekin AKPOLAT, Nurol ARIK, Şükrü ULUSOY
Regional Coordinators for Eastern Turkey:
Yılmaz SELÇUK, Reha ERKOÇ
Regional Coordinators for Southeastern Turkey:
Bünyamin IŞIKOĞLU, Emin YILMAZ, Asım GÖYMEN
Regional Coordinators for Adana and Çukurova Region:
Yahya SAĞLIKER, Uğur EKREN, Zeki GÜLOĞLU, Saime PAYDAŞ
Regional Coordinators for Antalya and Mediterranean Region:
Gülşen YAKUPOĞLU, Fevzi ERSOY, Alper DEMİRBAŞ
Communication and Assistance in Data Collection:
Executive Secretary: Mübeccel AKYÜZ
Central Registry Committee Secretary: Şükran AKPINAR
Project Management:
Omega Contract Research Organization
Project Managers:
Ebru MUTLU, Hakan YILMAZ
Assistant Project Manager
Kartal ÇETİNTÜRK
Regional Project Managers:
Öznur BİÇEROĞLU, Yeşim KOÇ (Ankara), Güliz ÖZGEN (İstanbul), Buket ÜNAK (İzmir),
Mesut BAHAR (Samsun)
Data Analysis and Reporting:
Oktay ÖZDEMİR, Ferit ÜN, Bülent SAKAOĞLU
Database Management and Software Development:
Berk ÖZDEMİR, Taner SUNDU, Taner VAROL
Data Entry Officers:
Fatih ELİTOĞ, Emre ÖZKAN
Review of Forms:
Hakan YILMAZ, Kartal ÇETİNTÜRK, Serpil ÇOBAN
Graphics and Translation:
Murat KİRTİŞ
ii
The Registry Books Published in Last 15 Years
1. Today of Hemodialysis in Istanbul, Istanbul 1989
Publishing Committee: Ekrem Erek, Serhat Perk. Publisher: Turkish Society of Nephrology,
number of pages: 48
2. Today of Nephrology, Dialysis and Transplantation in Turkey, 1990
Publishing Committee: Ekrem Erek, Serhan Dalmak. Publisher: Turkish Society of Nephrology,
number of pages: 97.
3. Nephrology, Dialysis and Transplantation in Turkey, Registry 1991
Publishing Committee: Ekrem Erek, Rezzan Ataman, Serran Dalmak, Süheyla Apaydın.
Publisher: Turkish Society of Nephrology, number of pages: 49.
4. Nephrology, Dialysis and Transplantation in Turkey, Registry 1992-1993
Publishing Committee: Ekrem Erek, Kamil Serdengeçti, Rezzan Ataman, Süheyla Apaydın.
Publishing Committee: Ekrem Erek, Gültekin Süleymanlar, Kamil Serdengeçti.
9. Nephrology, Dialysis and Transplantation in Turkey, Registry 1999 (including English version)
Central Registry Committee: Ekrem Erek, Gültekin Süleymanlar, Kamil Serdengeçti.
14. Nephrology, Dialysis and Transplantation in Turkey, Registry 2004 (English)
iii
DEMOGRAPHICS OF TURKEY
Background
:
Modern Turkey was founded in 1923 by Kemal ATATÜRK after a war
of independence, following the fall of the 620-years-old Ottoman
Empire. Under his leadership, the country adopted wide-ranging
social, legal, and political reforms.
Location
:
Southeastern Europe and southwestern Asia
Area
:
Total: 780.580 sq km
Population
:
73.330.000
Age structure
:
0-14 years: 26% (male 9.232.439/female 8.897.135)
15-64 years: 67.3% (male 23.806.367/female 23.053.536)
65 years and over: 6.7% (male 2.140.242/female 2.530.840)
(2005 est.)
Median age
:
Total: 27.7 years
Population growth rate
:
1.8% (2005 est.)
Life expectancy at birth
:
Total population: 72.36 years
Male: 69.94 years
Female: 74.91 years (2005 est.)
Total fertility rate
:
1.94 children born/woman (2005 est.)
Number of medical faculties :
35 state, 6 private (January 2001)
Number of physicians
:
95.192 (2002)
:
:
43.662
51.530
Number of nurses
:
70.270 (4020 private)
Per capita income
:
4250 $/year (2004)
specialists
general practitioners
iv
CONTENTS
Page
2004 Registry............................................................................................................................ 1
Clinical Nephrology ................................................................................................................... 3
Renal Replacement Therapies .................................................................................................. 7
Hemodialysis .................................................................................................................. 7
Peritoneal Dialysis......................................................................................................... 29
Renal Transplantation ................................................................................................... 43
Pediatric Nephrology............................................................................................................... 53
Pediatric Hemodialysis .................................................................................................. 55
Pediatric Peritoneal Dialysis .......................................................................................... 59
Pediatric Renal Transplantation..................................................................................... 63
Comparative Figures from World and Turkey .......................................................................... 65
Centers Included in the Registry.............................................................................................. 75
ABBREVIATIONS
APD ...................... Automated peritoneal dialysis
BP ........................ Blood pressure
CAPD ................... Continuous ambulatory peritoneal dialysis
CGN ..................... Chronic glomerulonephritis
CRF ...................... Chronic renal failure
DM........................ Diabetes mellitus
EPO...................... Erythropoietin
ESRD ................... End stage renal disease
GFR...................... Glomerular filtration rate
HD ........................ Hemodialysis
HT ........................ Hypertension
PD ........................ Peritoneal dialysis
pmp ...................... Per million population
RRT ...................... Renal replacement therapy
RTx....................... Renal transplantation
TIN ....................... Tubulointerstitial nephritis
TSN ...................... Turkish Society of Nephrology
v
2004 REGISTRY
Number of centers invited to Registry (including pediatric nephrology centers)............ 459
Number of centers that do not fit Registry inclusion criteria ........................................................ 9
Number of centers without HD unit................................................................................ 3
Number of centers where HD units were closed in 2004................................................ 5
Number of centers that could not be reached ................................................................ 1
Number of centers that fit Registry inclusion criteria .............................................................. 450
Number of non-responding centers ......................................................................................... 10
Number of responding centers and response rate............................................... 440 (97.8%)
Number of centers per million population................................................................................ 6.2
HD centers
Number of specialist physicians ................................................................................ 439
Number of general practitioners ................................................................................ 699
Total number of physicians ..................................................................................... 1138
Number of nurses ................................................................................................... 2827
Number of HD equipments...................................................................................... 5964
PD centers
Number of specialist physicians .................................................................................. 85
Number of general practitioners .................................................................................. 38
Total number of physicians ....................................................................................... 123
Number of nurses ..................................................................................................... 124
Pediatric nephrology centers
Number of centers invited to Registry ................................................................................. 32
Number of responding centers and response rate.................................................. 32 (100%)
Number of centers with HD units................................................................................. 23
Number of centers with PD units ................................................................................. 30
Number of centers where RTx is performed ................................................................ 15
1
CLINICAL NEPHROLOGY
Incident ESRD* patients in 2004
Pre-dialysis patients.............................................................................................. 30.8%
HD patients .......................................................................................................... 58.9%
PD patients............................................................................................................. 8.0%
Tx patients.............................................................................................................. 2.3%
Prevalent ESRD patients, as of the end of 2004
Pre-dialysis patients.............................................................................................. 25.5%
HD patients .......................................................................................................... 58.4%
PD patients........................................................................................................... 10.0%
Tx patients.............................................................................................................. 6.1%
Primary renal diseases in incident ESRD patients in 2004
Diabetes mellitus .................................................................................................. 25.3%
Hypertensive renal disease ................................................................................... 17.2%
Chronic glomerulonephritis ................................................................................... 13.4%
Other diseases ..................................................................................................... 20.5%
Etiology unknown ................................................................................................. 23.6%
Primary renal diseases in prevalent ESRD patients, as of the end of 2004
Diabetes mellitus .................................................................................................. 23.1%
Hypertensive renal disease ................................................................................... 19.8%
Chronic glomerulonephritis ................................................................................... 16.3%
Other diseases ..................................................................................................... 22.5%
* GFR less than 15 mL/min for non-diabetic patients and GFR less than 20 mL/min for diabetic patients are
accepted as ESRD.
3
Response rate by years
100
94.1
96.2
94.4
2002
2003
97.6
Percent
90
80
77.5
70
60
2000
2001
2004
Treatment modalities in incident RRT patients (2004)
100
84.1
% of pts.
80
60
40
11.6
20
3.3
0
HD
PD
Tx
Treatment modalities in prevalent RRT patients (2004)
100
% of pts.
80
78.4
60
40
13.4
20
8.2
0
HD
4
PD
Tx
Etiology of incident ESRD patients (2004)
Diabetes mellitus
25.3
Hypertensive renal disease
17.2
Chronic glomerulonephritis
13.4
5.8
Urologic disease
Chronic interstitial nephritis
4.0
Cystic renal disease
3.9
6.8
Miscellaneous
Etiology unknown
23.6
0
10
20
30
% of pts.
Etiology of prevalent ESRD patients (2004)
Diabetes mellitus
23.1
Hypertensive renal disease
19.8
Chronic glomerulonephritis
16.3
Urologic disease
5.7
Cystic renal disease
5.3
Chronic interstitial nephritis
4.9
6.6
Miscellaneous
Etiology unknown
18.3
0
10
20
30
% of pts.
5
TRENDS IN CLINICAL NEPHROLOGY BY YEARS
RRT patients with diabetic nephropathy by years
30
25.3
25.3
% of pts.
22.8
20
15.3
18.1
16.9
16.4 15.8
13.6
10
4.6
4.5
0
1991 1993 1995 1996 1997 1998 1999 2000 2001 2003 2004
RRT patients with cystic renal disease by years
% of pts.
15
10
6.6
6.0
5
5.8
4.5
4.1
4.2
3.9
2.8
2.5
0
1991
1996
1997
1998
1999
2000
2001
2003
2004
Discussion

Evaluation is performed based on the results provided by 440 centers (number of pediatric
nephrology centers: 32).

In the year 2004, the point prevalence and incidence rates of ESRD treated with RRT are
found as 444 pmp and 123 pmp, respectively. There is an increase in both point prevalence
and incidence rates as compared to last year.

First three etiologic diseases causing chronic renal disease among incident ESRD patients in
2004 are found as diabetes mellitus (25.3%), hypertension (17.2%) and chronic glomerulonephritis
(13.4%), respectively.

First three etiologic diseases causing chronic renal disease among prevalent ESRD patients as of
the end of 2004 are found as diabetes mellitus (23.1%), hypertension (19.8%) and chronic
glomerulonephritis (16.3%), respectively.
6
RENAL REPLACEMENT THERAPIES
HEMODIALYSIS
Incident regular HD patients in 2004
Male ..................................................................................................................... 54.9%
Female ................................................................................................................. 45.1%
0-15 years of age.................................................................................................... 0.4%
16-19 years of age.................................................................................................. 1.3%
20-44 years of age................................................................................................ 21.7%
45-64 years of age................................................................................................ 48.9%
65-74 years of age................................................................................................ 20.8%
75+ years of age..................................................................................................... 6.8%
Prevalent regular HD patients as of the end of 2004 .................................................... 25.321
Male ..................................................................................................................... 56.2%
Female ................................................................................................................. 43.8%
0-15 years of age.................................................................................................... 0.3%
16-19 years of age.................................................................................................. 1.4%
20-44 years of age................................................................................................ 28.8%
45-64 years of age................................................................................................ 42.9%
65-74 years of age................................................................................................ 20.7%
75+ years of age..................................................................................................... 5.8%
Frequency of HD sessions in regular HD patients, as of the end of 2004
Once weekly ........................................................................................................... 1.6%
Twice weekly ........................................................................................................ 13.6%
Three times weekly ............................................................................................... 84.8%
Duration of dialysis in regular HD patients, as of the end of 2004
0-5 years .............................................................................................................. 69.6%
6-10 years ............................................................................................................ 22.4%
11-15 years ............................................................................................................ 6.2%
16-20 years ............................................................................................................ 1.5%
20+ years ............................................................................................................... 0.2%
Number of dialysers consumed in 2004 ....................................................................... 3.234.687
Synthetic .............................................................................................................. 54.0%
Semi-synthetic ...................................................................................................... 35.8%
High-flux ................................................................................................................. 8.9%
Cuprophane............................................................................................................ 1.3%
Percentage of regular HD patients with urea reduction rate higher than 0.65,
as of the end of 2004 ........................................................................................................ 68.1%
Percentage of HD centers where urea kinetics model is used in 2004 ............................... 62.2%
Kt/V values in regular HD patients, as of the end of 2004
<0.80 ...................................................................................................................... 2.2%
0.81-1.00 ................................................................................................................ 8.5%
1.10-1.20 .............................................................................................................. 25.6%
1.21-1.80 .............................................................................................................. 58.7%
>1.80 ....................................................................................................................... 50%
Types of vascular access in regular HD patients, as of the end of 2004
AV fistula (native) ................................................................................................. 90.1%
Persistent (tunnel) catheter ..................................................................................... 3.5%
AV graft (prosthesis) ............................................................................................... 2.6%
Miscellaneous......................................................................................................... 3.7%
7
AV fistula localization in regular HD patients, as of the end of 2004
Forearm 1/3 distal region ...................................................................................... 42.0%
Forearm 1/3 mid-region ........................................................................................ 25.0%
Arm 1/3 distal ....................................................................................................... 23.7%
Snuff-box ................................................................................................................ 8.5%
Femoral .................................................................................................................. 0.8%
Anticoagulation method in regular HD patients, as of the end of 2004
Standard heparinization ........................................................................................ 56.5%
Low-molecular weight heparinization .................................................................... 42.5%
Regional heparinization .......................................................................................... 0.1%
Miscellaneous......................................................................................................... 0.9%
Hypertension in regular HD patients, as of the end of 2004
Hypertensive ........................................................................................................ 40.7%
BP >140/90 mmHg, on antihypertensive treatment ................................... 13.5%
BP >140/90 mmHg, not on antihypertensive treatment ............................... 6.9%
BP <140/90 mmHg, on antihypertensive treatment ................................... 20.3%
Normotensive (BP <140/90 mmHg, not on antihypertensive treatment) ................. 59.3%
Cardiovascular diseases in regular HD patients, as of the end of 2004
Left ventricular hypertrophy................................................................................... 19.3%
Coronary heart disease........................................................................................... 9.5%
Heart failure............................................................................................................ 6.8%
Arrythmia ................................................................................................................ 5.5%
Miscellaneous......................................................................................................... 5.2%
Percentage of regular HD patients with hypoalbuminemia (less than 3.5 g/dL),
as of the end of 2004 ........................................................................................................ 12.9%
Erythropoietin treatment in regular HD patients, as of the end of 2004
Percentage of HD patients on erythropoietin treatment ......................................... 62.8%
Percentage of HD patients with erythropoietin resistance ........................................ 7.7%
Iron treatment in regular HD patients, as of the end of 2004
HD patients on iron treatment ............................................................................... 58.9%
Oral iron treatment .................................................................................................. 5.0%
Parenteral iron treatment ...................................................................................... 53.9%
Serum intact PTH levels (pg/mL) in regular HD patients, as of the end of 2004
<100 ..................................................................................................................... 26.7%
100-300 ................................................................................................................ 36.6%
300-500 ................................................................................................................ 17.7%
500-1000 .............................................................................................................. 11.7%
>1000 ..................................................................................................................... 6.1%
Phosphate-binding treatment in regular HD patients, as of the end of 2004
HD patients on phosphate-binding treatment ........................................................ 87.3%
Calcium acetate.................................................................................................... 66.7%
Calcium carbonate................................................................................................ 13.3%
Aluminium hydroxide .............................................................................................. 4.7%
Sevelamer .............................................................................................................. 2.0%
Miscellaneous......................................................................................................... 0.7%
Active vitamin D treatment in regular HD patients, as of the end of 2004
HD patients on vitamin D treatment....................................................................... 41.3%
Oral vitamin D treatment ....................................................................................... 14.3%
IV vitamin D treatment .......................................................................................... 27.0%
8
Hepatitis serology in regular HD patients, as of the end of 2004
HBsAg (+)............................................................................................................... 4.9%
Anti-HCV Ab (+).................................................................................................... 19.3%
Both HBsAg and Anti-HCV Ab (+) ........................................................................... 1.5%
Deaths in regular HD patients, in 2004
Deaths due to any cause .......................................................................... 3.441 (14.4%)
within the first 90 days of dialysis ................................................................ 4.5%
after 90 days of dialysis .............................................................................. 9.9%
Causes of death
Deaths due to cardiovascular causes ....................................................... 46.7%
Deaths due to cerebrovascular accidents ................................................. 12.6%
Deaths due to malignancies...................................................................... 10.4%
Deaths due to infections ............................................................................. 9.7%
Deaths due to other causes ...................................................................... 20.4%
9
Age distribution of incident regular HD patients (2004)
% of pts.
80
60
48.9
40
21.7
20
0.4
1.3
0-15
16-19
20.8
6.8
0
20-44
45-64
65-74
75+
Years of age
Mean age of incident regular HD patients (2004)
Years of age
60
53.2
54.4
53.8
Male
Female
Total
40
20
0
Age distribution of incident regular HD patients with
diabetic nephropathy (2004)
51.8
% of pts.
60
40
29.0
11.9
20
0.3
0.3
0-15
16-19
6.7
0
20-44
45-64
65-74
75+
Years of age
10
Age distribution of prevalent regular HD patients (2004)
60
% of pts.
42.9
40
28.8
20.7
20
0.3
1.4
0-15
16-19
5.8
0
20-44
45-64
65-74
75+
Years of age
Age distribution of prevalent regular HD patients with
diabetic nephropathy (2004)
52.3
% of pts.
60
40
28.6
13.0
20
0.0
0.2
0-15
16-19
6.0
0
20-44
45-64
65-74
75+
Years of age
Frequency of HD sessions in regular HD patients (2004)
84.8
% of pts.
90
60
30
13.6
1.6
0
1/week
2/week
3/week
11
Distribution of dialyser membranes in regular HD patients
(2004)
% of pts.
60
54.0
35.8
40
20
8.9
1.3
0
Synthetic
Semisynthetic
High-flux
Cuprophane
Urea Reduction Rate (URR) in regular HD patients (2004)
% of pts.
80
68.1
60
40
31.9
20
0
≤0.65
>0.65
Urea kinetics model usage in HD centers (2004)
80
% of centers
62.2
60
40
37.8
20
0
Yes
12
No
60.2
28.7
2/week
7.9
12.8
3/week
4.7
2.0
20
7.9
40
25.2
60
3.6
% of pts.
80
47.1
Kt/V ratios in regular HD patients (2004)
0
≤0.80
0.81-1.00
1.01-1.20
1.21-1.80
>1.80
Types of vascular access in regular HD patients (2004)
90.1
100
% of pts.
80
60
40
20
3.5
2.6
3.7
Persistent
(tunnel) catheter
AV graft
(prosthesis)
Misc.
0
AV fistula
(native)
70.7
29.3
61.3
38.7
29.3
40
29.3
60
70.7
73.4
80
26.6
% of pts.
100
70.7
AV fistula localization in regular HD patients (2004)
Right
Left
20
0
Forearm
1/3 distal
region
Forearm
1/3 mid
region
Arm 1/3
distal
region
Femoral
region
Snuff-box
13
AV fistula localization in regular HD patients (2004)
60
% of pts.
42.0
40
25.0
23.7
20
8.5
0.8
0
Forearm 1/3 Forearm 1/3
Arm 1/3
distal region mid region distal region
Snuff-box
Femoral
region
Anticoagulation methods used in regular HD patients (2004)
% of pts.
60
56.5
42.5
40
20
0.1
0.9
Regional
heparinization
Misc.
0
Standard
heparinization
Low molecular
weight
heparinization
Blood pressure status in regular HD patients (2004)
80
% of pts.
59.3
60
40
20.3
20
6.9
13.5
0
BP <140/90 mmHg
untreated
14
BP <140/90 mmHg
treated
BP >140/90 mmHg
untreated
BP >140/90 mmHg
treated
Cardiovascular diseases in regular HD patients (2004)
Left ventricle hypertrophy
19.3
Heart failure
6.8
Arrythmia
5.5
Angina pectoris
5.5
Peripheral arterial disease
2.9
Coronary by-pass surgery
1.7
Acute myocardial infarction
1.2
Cerebrovascular accident
1.1
Coronary angioplasty / stent
1.1
Pericarditis
0.7
Infective endocarditis
0.5
0
5
10
15
20
% of pts.
Serum albumin levels in regular HD patients (2004)
87.1
% of pts.
90
60
30
12.9
0
<3.5 g/dL
>3.5 g/dL
15
Erythropoietin usage in regular HD patients (2004)
80
% of pts.
62.8
60
37.2
40
20
0
Yes
No
Regular serum ferritin measurement in HD centers (2004)
79.5
% of centers
80
60
40
20.5
20
0
Yes
No
Iron treatment in regular HD patients (2004)
60
53.9
% of pts.
41.1
40
20
5.0
0
Oral
16
Parenteral
None
Renal bone disease tests performed in HD centers (2004)
Routine biochemical tests
97.5
Bone X-rays
74.7
Serum intact parathormone
70.2
Parathyroid scintigraphy
27.5
Bone-specific alkaline phosphatase
21.6
13.4
Serum aluminium
Serum Vit-D metabolites
8.2
Deferoxamine test
6.0
Bone biopsy
4.2
Serum osteocalcin
3.7
0
20
40
60
80
100
% of centers
Serum intact parathormone levels in regular HD patients
(2004)
36.6
% of pts.
40
26.7
17.7
20
11.7
6.1
0
<100
100-300
300-500
500-1000
>1000
pg/mL
17
Phosphorus binding agents used in regular HD patients (2004)
Calcium acetate
66.7
Calcium carbonate
13.3
Aluminium hydroxide
4.7
2.0
Sevelamer
Misc.
0.7
None
12.7
0
20
40
60
80
% of pts.
Active vitamin D used in regular HD patients (2004)
58.7
% of pts.
60
40
27.0
20
14.3
0
Oral
18
IV
None
Hepatitis serology in regular HD patients (2004)
19.3
% of pts.
20
10
4.9
1.5
0
HBsAg (+)
Anti-HCV (+)
HBsAg (+) and
Anti-HCV (+)
Duration of dialysis in regular HD patients (2004)
% of pts.
80
69.6
60
40
22.4
20
6.2
1.5
0.2
16-20
>20
0
≤5
6-10
11-15
Years
19
Causes of death in regular HD patients (2004)
Cardiovascular
46.7
Cerebrovascular
accident
12.6
Malignancy
10.4
Infection
9.7
Hepatic failure
1.9
Pulmonary emboli
1.2
Misc.
17.3
0
10
20
30
40
50
% of cardiovascular deaths
% of total deaths
Deaths due to cardiovascular diseases
in regular HD patients (2004)
60
45.6
44.3
40
20
7.2
2.5
0
Heart failure
Ischemic heart
disease
Arrythmia
Misc.
Discussion

20
Evaluation is performed based on the results provided by 395 hemodialysis (HD) centers. The
number of the centers contributed (n: 388), the number of HD equipments (n: 5964), and the
number of HD patients (n: 25321) are increased by 13.0% compared to last year. The proportion
of patients who are 15 years old or younger is 0.3%. With a percentage of 79.0%, HD is the most
commonly used RRT method in Turkey. The total number of physicians and nurses are 1138 and
2829, respectively. There are some differences in numbers as compared to the numbers from
Ministry of Health. There are several reasons of this: unlike the report of Ministry of Health, this
report does not include;
o
the incident HD patients of 2005,
o
the numbers of died HD patients,
o
the potential HD patients of the centers newly established their HD equipments.

The proportion of diabetic patients among the HD patients is increased from 19.2% to %23.0 and
this fact shows that diabetes mellitus, as a cause of ESRD, has an increasing rate in Turkey as
well.

The age range of HD patients: 49.8% of all patients and 52.4% of diabetic patients are in the age
range of 45 and 64.

Frequency of HD sessions: three times weekly for 84.8%, twice weekly for 13.6%, and once
weekly for 1.6%. There is an increase in the frequency of 3 sessions/week compared to last year.

A total of 3.235.000 dialysers are used in 385 centers in the year 2004. Decrease in cuprophane
usage (1.3%) continues while there is a significant increase in synthetic membrane usage.
Synthetic membranes are the most commonly prescribed membranes (54%) in the year 2004.
High-flux membrane usage is 8.9%.

There is an increase in urea kinetics model usage in the evaluation of dialysis sufficiency; it is
used by 62.2% of the centers. Urea Reduction Rate is lower than 0.65 in 68.1% of chronic HD
patients. Kt/V is higher than 1.2 in 63.7% of the patients.

AV fistula is the vascular access route in 90.1% of HD patients and is opened on left arm with a
proportion of over 70%. In 57.1% of the patients, dialysis is continued with the initial AV fistula. In
42.5% of the HD patients, low molecular weight heparine is used for anticoagulation.

The frequency of hypertension in HD patients is found as 40.7%.

Serum albumin level which is one of the reliable indicators of nutrition is lower than 3.5 g/dL in
12.9% of the HD patients. Results are better as compared to last year. The proportion of the
patients whose serum albumin level is higher than 4.0 g/dL is 33.6%.

The frequency of EPO usage in HD patients is 62.8% and there is a decrease when compared to
last year. Target HB level (>11 g/dL) is reached in only 58.3% of the patients receiving EPO. EPO
resistance is found in 7.7% of HD patients. This figure shows decrease as compared to last year
(10.6%). Iron treatment is administered in 58.9% of HD patients (oral: 5.0%, parenteral: 53.9%).
Routine serum ferritin tests are performed in 79.5% of the centers.

Routine biochemical tests (97.5%), bone X-rays (74.7%), and parathyroid scintigraphy (70.2%) are
the most commonly used tests for renal bone disease in HD patients. The proportions of patients
with iPTH level <100 pg/mL and >1000 pg/mL are 26.7% and 6.1%, respectively. Calcium acetate
(66.7%), calcium carbonate (13.3%), and sevelamer (2.0%) are used as phosphorus binding
agents in HD patients. There is a decrease in the rates of oral (14.3%) and IV (27%) active vitamin
D usage compared to last year. Parathyroidectomy is performed in 226 patients. Venous
bicarbonate level test is practiced in only 6.6% of the centers, for acidose follow up.

There found no change in the frequency of HBV infection in HD patients compared to last year.
The frequency of anti-HCV (+) patients continues to decrease (from 24.6% to 19.3%).

Dialysis duration is longer than 6 years in more than 30% of HD patients. 31.0% of the HD
patients died within the first 3 months, which is same as last year. With a rate of 46.7%,
cardiovascular diseases are the most common cause of death in HD patients. Cerebrovascular
accident, malignancy and infection come after it, respectively.

HD is the most commonly used RRT method in ESRD patients in Turkey (79%). While the number
of patients keeps increasing, improvements in HD conditions and efforts to provide a more
qualified dialysis are being carried on.
21
TRENDS IN REGULAR HEMODIALYSIS THERAPY BY YEARS
12196
11339
7014
1996
9658
6527
5000
1995
3069
10000
5400
15000
3494
Count
20000
14086
23387
20600
25000
18815
30000
25321
Number of regular HD patients by years
2004
2003
2002
2001
2000
1999
1998
1997
1993
1991
1990
0
Frequency of HD sesions in regular HD patients by years
% of pts.
100
80
60
40
20
1/week
2/week
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1993
1991
0
3/week
Types of dialysate used in regular HD patients by years
% of pts.
100
80
60
40
20
Bicarbonate
22
2002
2001
2000
1999
1998
1997
1995
0
Acetate
90.1
87.5
83.0
100
88.4
Types of vascular access in regular HD patients by years
% of pts.
80
60
9.1
2.5
3.5
3.5
5.5
3.5
2.6
3.8
20
14.1
2.9
40
1998
1999
2003
2004
0
AV fistula
Catheter
Graft
Other
Hypoalbuminemia (<3.5 g/dL) in regular HD patients
by years
40
34.5
% of pts.
30
19.8
23.0
20
18.3
16.2 14.7 17.3
19.2
15.4
12.9
10
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Erythropoietin usage in regular HD patients by years
80
63.4
55.0
60
% of pts.
67.6 69.5 69.5 69.3 66.5 65.5
62.8
44.2
40
38.0
20
0
1991 1993 1996 1997 1998 1999 2000 2001 2002 2003 2004
23
% of pts.
12
9
Erythropoietin resistance in regular HD patients
by years
10.6
9.5
7.7
6
3
0
2002
2003
2004
Iron treatment in regular HD patients by years
80
73.5
60.4
58.9
2003
2004
% of pts.
60
40
20
0
1995
Active vitamin D usage in regular HD patients by years
90
85.0
73.6
70.6
% of pts.
62.2
60
50.5
45.2
40.4
41.3
2003
2004
30
0
1995
24
1998
1999
2000
2001
2002
Frequency of HBsAg (+) regular HD patients by years
15.0
15
12.7
11.1 10.5
% of pts.
10.0
10
8.1
7.9
7.5
7.6
6.5
5.9
6.4
5
0
1991 1993 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Frequency of Anti-HCV (+) regular HD patients by years
60
54.6
% of pts.
41.7
36.2
40
29.6
28.8
26.3
23.2
20.8
20
0
1997
1998
1999
2000
2001
2002
2003
2004
% of total deaths
Deaths due to cardiovascular disease
in regular HD patients by years
60
50.6
51.9
1995
1996
50.0
48.4
45.5
45.0
46.4
49.0
46.7
1997
1998
1999
2000
2002
2003
2004
40
20
0
25
% of total deaths
Deaths due to cerebrovascular accident
in regular HD patients by years
20
15
10.6
11.2
1995
1996
13.1
12.9
1997
1998
15.0
13.4
12.6
12.6
2002
2003
2004
10
5
0
1999
% of total deaths
Deaths due to infections in regular HD patients by years
15
11.6
9.3
10
10.0
11.6
10.4
9.9
2001
2002
9.7
8.0
7.8
5
0
1996
1997
1998
1999
2000
2003
2004
% of total deaths
Deaths due to malignancies in regular HD patients
by years
26
12
9
6.0
6.5
1998
1999
10.4
9.1
9.1
8.9
2001
2002
2003
6
3
0
2004
% of total deaths
Deaths due to hepatic failure in regular HD patients
by years
10
8
4.8
6
4
2.8
3.0
1996
1997
3.5
2.8
3.1
2.4
1.9
2003
2004
2
0
1998
1999
2001
2002
Discussion

The proportion of regular HD patients is increased by 15-20% in the last 15 years.

The increase in the weekly HD sessions is more significant for 3 sessions/week.

Hygienic conditions have provided the significant decrease in the percentage of HBsAg (+) regular
HD patients through years. The decrease in the proportion of anti-HCV (+) patients can be
prevented by hygienic conditions, too.

Acetate usage as a dialysate has almost left its place to bicarbonate.

In Turkey, the most commonly preferred vascular access route is native AV fistula. Unlike USA the
proportion of graft is too small.

The percentage of EPO usage has showed no significant change through years, while there is an
decrease in vitamin D usage, which is a result of . This decrease is a result of strict follow-up of
patients.

Hypolbuminemia is decreased to 12.9% in 2004. This result is very satisfactory as a matter of
nutrition.

Decrease in iron treatment is observed through 15 years.

Through 15 years there observed no significant change in the percentage of deaths due to
cardiovascular, cerebrovascular accident or infection.

There is a slight increase in the proportion of deaths due to malignancy.

Preventing the factors causing resistance, the frequency of EPO resistance is decreased.
27
PERITONEAL DIALYSIS
Incident CAPD patients in 2004 ....................................................................................... 1.230
Male ..................................................................................................................... 52.1%
Female ................................................................................................................. 47.9%
0-15 years of age.................................................................................................... 1.9%
16-19 years of age.................................................................................................. 2.1%
20-44 years of age................................................................................................ 34.1%
45-64 years of age................................................................................................ 42.4%
65-74 years of age................................................................................................ 15.9%
75+ years of age..................................................................................................... 3.7%
Incident APD patients in 2004 ............................................................................................ 271
Male ..................................................................................................................... 57.6%
Female ................................................................................................................. 42.4%
0-15 years of age.................................................................................................... 1.5%
16-19 years of age.................................................................................................. 1.8%
20-44 years of age................................................................................................ 46.1%
45-64 years of age................................................................................................ 38.0%
65-74 years of age................................................................................................ 10.3%
75+ years of age..................................................................................................... 2.2%
Prevalent PD patients as of the end of 2004 ................................................................... 3.320
Duration of dialysis in PD patients, as of the end of 2004
0-5 years .............................................................................................................. 87.8%
6-10 years ............................................................................................................ 11.7%
11-15 years ............................................................................................................ 0.5%
Hypertension in PD patients, as of the end of 2004
Hypertensive ........................................................................................................ 51.3%
BP >140/90 mmHg, on antihypertensive treatment ................................... 26.4%
Normotensive (BP < 140/90 mmHg, not on antihypertensive treatment) ................ 38.7%
Cardiovascular diseases in PD patients, as of the end of 2004
Heart failure............................................................................................................ 3.8%
Arrythmia ................................................................................................................ 3.1%
Miscellaneous......................................................................................................... 5.2%
Percentage of PD patients with hypoalbuminemia (less than 3.5 g/dL),
as of the end of 2004 ........................................................................................................ 28.9%
Erythropoietin treatment in PD patients, as of the end of 2004
Percentage of PD patients on erythropoietin treatment.......................................... 56.7%
Percentage of PD patients with erythropoietin resistance ........................................ 8.4%
Iron treatment in PD patients, as of the end of 2004
PD patients on iron treatment ............................................................................... 59.8%
Oral iron treatment ................................................................................................ 44.4%
Parenteral iron treatment ...................................................................................... 15.4%
29
Serum intact PTH levels (pg/mL) in PD patients, as of the end of 2004
<100 ..................................................................................................................... 25.8%
100-300 ................................................................................................................ 33.0%
300-500 ................................................................................................................ 22.2%
500-1000 .............................................................................................................. 11.8%
> 1000 .................................................................................................................... 7.2%
Phosphate-binding treatment in PD patients, as of the end of 2004
PD patients on phosphate-binding treatment ......................................................... 86.2%
Calcium acetate.................................................................................................... 56.4%
Calcium carbonate................................................................................................ 20.0%
Aluminium hydroxide .............................................................................................. 6.1%
Sevelamer .............................................................................................................. 2.5%
Miscellaneous......................................................................................................... 1.2%
Active vitamin D treatment in PD patients, as of the end of 2004
PD patients on vitamin D treatment ....................................................................... 40.2%
Oral vitamin D treatment ....................................................................................... 37.8%
IV vitamin D treatment ............................................................................................ 2.4%
Hepatitis serology in PD patients, as of the end of 2004
HBsAg (+)............................................................................................................... 4.8%
Anti-HCV Ab (+)...................................................................................................... 8.9%
Complications in PD patients, in 2004
Percentage of PD patients who experienced peritonitis ......................................... 29.3%
Rate of peritonitis...................................................................................... 1/29.7 months
Other complications
Hyperlipidemia ......................................................................................... 23.4%
Obesity....................................................................................................... 8.4%
Hernia ........................................................................................................ 7.2%
Psychological problems .............................................................................. 6.0%
Insufficient dialysis ..................................................................................... 5.6%
Hyperglycemia ........................................................................................... 3.1%
Causes of deaths in PD patients, in 2004
Deaths due to cardiovascular causes .................................................................... 37.1%
Deaths due to infections ....................................................................................... 17.3%
Deaths due to cerebrovascular accident ................................................................. 8.2%
Deaths due to malignancies .................................................................................... 3.3%
Deaths due to other causes .................................................................................. 34.0%
30
Age distribution of incident CAPD patients (2004)
% of pts.
50
42.4
34.1
40
30
15.9
20
10
1.9
2.1
0-15
16-19
3.7
0
20-44
45-64
65-74
75+
Years of age
Age distribution of incident APD patients (2004)
46.1
% of pts.
50
38.0
40
30
20
10
10.3
1.5
1.8
0-15
16-19
2.2
0
20-44
45-64
65-74
75+
Years of age
Mean age of incident PD patients (2004)
Years of age
60
48.7
48.2
48.5
Male
Female
Total
40
20
0
31
Age distribution of incident PD patients with diabetic
nephropathy (2004)
54.4
% of pts.
60
40
22.3
18.0
20
4.6
0.0
0.6
0-15
16-19
0
20-44
45-64
65-74
75+
Years of age
Blood pressure status in PD patients (2004)
40
38.7
% of pts.
28.6
26.4
20
6.3
0
BP <140/90 mmHg
untreated
32
BP <140/90 mmHg
treated
BP >140/90 mmHg
untreated
BP >140/90 mmHg
treated
Cardiovascular diseases in PD patients (2004)
12.8
Heart failure
3.8
3.1
Arrythmia
2.3
Angina pectoris
2.1
0.8
0.8
0.7
0.7
0.5
Pericarditis
0.5
0
5
10
15
% of pts.
Serum albumin levels in PD patients (2004)
% of pts.
80
71.1
60
40
28.9
20
0
<3.5 g/dL
>3.5 g/dL
33
Complications other than peritonitis in PD patients (2004)
23.4
Hyperlipidemia
8.4
Obesity
7.2
Hernia
Psychological
problems
6.0
Insufficient dialysis
5.6
Drainage dysfunction
4.4
Hyperglycemia
3.1
0
10
20
30
% of pts.
Erythropoietin usage in PD patients (2004)
60
56.7
% of pts.
43.3
40
20
0
Yes
34
No
Iron treatment in PD patients (2004)
50
44.4
40.2
% of pts.
40
30
15.4
20
10
0
Oral
Parenteral
None
Serum intact parathormone levels in PD patients (2004)
% of pts.
40
30
33.0
25.8
22.2
20
11.8
7.2
10
0
<100
100-300
300-500
500-1000
>1000
pg/mL
Phosphorus binding agents used in PD patients (2004)
Calcium acetate
56.4
Calcium carbonate
20.0
Aluminium hydroxide
6.1
Sevelamer
2.5
Misc.
1.2
None
13.8
0
20
40
60
% of pts.
35
Active vitamin D used in PD patients (2004)
59.8
% of pts.
60
40
37.8
20
2.4
0
Oral
IV
None
Hepatitis serology in PD patients (2004)
10
8.9
% of pts.
8
6
4.8
4
2
0.7
0
HBsAg (+)
Anti-HCV (+)
HBsAg (+) and
Anti-HCV (+)
Duration of dialysis in PD patients (2004)
% of pts.
100
87.8
80
60
40
11.7
20
0.5
0.0
11-15
>15
0
≤5
6-10
Years
36
Causes of death in PD patients (2004)
37.1
Cardiovascular
17.3
Infection
Cerebrovascular
accident
8.2
Malignancy
3.3
Pulmonary emboli
2.2
Hepatic failure
0.5
Misc.
31.3
0
10
20
30
40
% of total deaths
% of cardiovascular deaths
Deaths due to cardiovascular diseases in PD patients (2004)
60
53.3
40
32.6
20
8.1
5.9
Arrythmia
Misc.
0
Ischemic heart
disease
Heart failure
37
Discussion

Evaluation is performed based on the results provided by 51 centers performing chronic peritoneal
dialysis. There are 48 certificated PD nurses working in these centers. There are 2683 CAPD
patients and 637 APD patients as of the end of 2004. The proportion of pediatric patients in CAPD
and APD are 1.9% and 1.5%, respectively.

The frequency of peritonitis is found as 29.7 patient-months and there is a significant improvement
compared to last year.

Hypertension (61.3%) and hyperlipidemia (23.4%) are the most common non-infectious
complications. Serum albumin level is lower than 3.5 g/dL in 28.9% of the PD patients. This figure
is higher compared to last year.

There is no difference in EPO usage (56.7%) in PD patients. Target HB level (<11 g/dL) is
reached in only 64.6% of the patients receiving EPO. EPO resistance is found in 8.4% of PD
patients. Iron treatment is administered in 59.8% of PD patients (oral: 44.4%, parenteral: 15.4%).
Routine serum ferritin tests are performed in 79.5% of the centers.

The proportion of patients with iPTH level <100 pg/mL and >1000 pg/mL are 25.8% and 7.2%,
respectively. Calcium acetate (56.4%), calcium carbonate (20%), and sevelamer (2.5%) are used
as phosphorus binding agents in PD patients. There is a decrease in the rates of oral (37.8%) and
IV (2.4%) active vitamin D usage compared to last year. Parathyroidectomy is performed in 47 PD
patients.

When compared to last year, there found a decrease in the frequency of HBsAg (+) and Anti-HCV
(+) patients; (4.8% and 8.9%, respectively).

With a rate of 37.1%, cardiovascular disease is the most common cause of death in PD patients
and infections and cerebrovascular accidents come after, respectively. Cause of death ranking is
similar to the previous years.
38
TRENDS IN PERITONEAL DIALYSIS THERAPY BY YEARS
Number of PD patients by years
3320
3500
3000
2556
2728
Count
2500
1927
1787 1903
2000
1500
1194 1111
1030 1124
1000
500
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Hypoalbuminemia (<3.5 g/dL) in PD patients by years
% of pts.
60
40
36.0
40.2
36.7
34.9
25.3 23.5
22.7
30.4 30.8 28.9
20
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Erythropoietin usage in PD patients by years
80
62.3
% of pts.
60
49.8
55.2
55.8 53.1 56.7
43.8 43.0 42.5
40
23.4
20
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
39
Erythropoietin resistance in PD patients by years
20
15.3
% of pts.
15
10.0
10
8.4
5
0
2002
2003
2004
Iron treatment in PD patients by years
80
63.7
59.8
% of pts.
60
40
20
0
2003
2004
Active vitamin D usage in PD patients by years
80
% of pts.
60
56.8
47.2
53.7
56.9
47.4
38.7
40
42.8
40.2
2003
2004
20
0
1997
40
1998
1999
2000
2001
2002
Frequency of HBsAg (+) PD patients by years
14.2
15
% of pts.
11.0
10.5
9.2
10
8.6
7.2
5.8
5.6
5.6
5.5
5
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Frequency of Anti-HCV (+) PD patients by years
25
21.3
% of pts.
20
21.3
20.8
21.3
16.7
15.1
15
10
13.8
11.3
9.6
7.3
5
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
% of total deaths
Deaths due to cardiovascular diseases in PD patients
by years
49.2
50
40
39.5
42.4
41.7
1997
1998
46.3
42.7
42.4
31.9
37.1
30
20
10
0
1995
1996
1999
2001
2002
2003
2004
41
% of total deaths
Deaths due to cerebrovascular accident in PD patients
by years
20
15
15.9
13.0 12.7
10.6 10.2
11.7
9.8
13.7
11.9
8.2
10
5
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
% of total deaths
Deaths due to infections in PD patients by years
30
23.7
26.1
23.9
20.8
20
14.4 12.8
11.1
14.2
18.2 17.3
10
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
% of total deaths
Deaths due to malignancies in PD patients by years
4.7
5
4
3.2
1999
2000
3.3
2.5
3
1.8
2
1
3.8
3.4
0.6
0.6
1995
1996
0
1997
1998
2002
2003
2004
Discussion

Starting from 1995 number of the PD patients shows an increasing trend.

The increase in the proportion of patients receiving EPO is significant.

Cardiovascular diseases are the most significant cause of death for 15 years.

The proportion of HBsAg (+) PD patients varies from year to year, while the frequency of anti-HCV
(+) PD patients is higher between the years 1997-2000 as compared to last 5 years.
42
RENAL TRANSPLANTATION
Incident RTx patients in 2004 ............................................................................................. 665
Male ..................................................................................................................... 68.0%
Female ................................................................................................................. 32.0%
0-15 years of age.................................................................................................... 4.1%
16-19 years of age.................................................................................................. 5.6%
20-44 years of age................................................................................................ 73.7%
45-64 years of age................................................................................................ 16.7%
65+ years of age..................................................................................................... none
Living donor .......................................................................................................... 72.1%
Related .................................................................................................... 85.6%
Spouse ..................................................................................................... 12.9%
Non-related ................................................................................................ 1.5%
Cadaver................................................................................................................ 27.9%
Prevalent RTx patients as of the end of 2004 ................................................................. 3.395
Hypertension in RTx patients, as of the end of 2004
Hypertensive ........................................................................................................ 71.8%
BP >140/90 mmHg, on antihypertensive treatment ..................................... 9.5%
Normotensive (BP <140/90 mmHg, not on antihypertensive treatment) ................. 28.2%
Cardiovascular diseases in RTx patients, as of the end of 2004
Arrythmia ................................................................................................................ 0.9%
Heart failure............................................................................................................ 0.5%
Miscellaneous......................................................................................................... 0.7%
Hepatitis serology in RTx patients, as of the end of 2004
HBsAg (+)............................................................................................................... 1.4%
Anti-HCV Ab (+)...................................................................................................... 7.9%
Status of the incident RTx patients, as of the end of 2004
Functioning graft ................................................................................................... 80.3%
Allograft dysfunction ............................................................................................. 12.6%
Returned to HD....................................................................................................... 3.8%
Died ....................................................................................................................... 3.3%
Causes of graft loss in RTx patients, as of the end of 2004
Chronic rejection................................................................................................... 48.9%
Death ................................................................................................................... 38.4%
Relapse of the primary disease ............................................................................... 4.7%
Acute rejection........................................................................................................ 4.1%
Primary non-functioning .......................................................................................... 2.8%
Misc........................................................................................................................ 1.1%
Causes of deaths in RTx patients, in 2004
Deaths due to infections ....................................................................................... 51.1%
Deaths due to cardiovascular causes .................................................................... 25.5%
Deaths due to cerebrovascular accident ................................................................. 6.4%
Deaths due to malignancies .................................................................................... 4.3%
Deaths due to other causes .................................................................................. 12.7%
43
Age distribution of incident RTx patients (2004)
73.7
% of pts.
80
60
40
16.7
20
4.1
5.6
0-15
16-19
0.0
0
20-44
45-64
65+
Years of age
Living
16-19
20-44
45-64
0.0
0
0-15
Cadaver
0.0
8.1
4.2
20
6.5
40
15.7
22.8
60
2.7
% of pts.
80
69.7
69.2
Age distribution of incident RTx patients by donor type
(2004)
65+
Years of age
Mean age of incident RTx patients (2004)
Years of age
40
34.5
32.9
Male
Female
36.3
32.8
34.0
Cadaver
Total
20
0
44
Living
Hepatitis serology in RTx patients (2004)
10
7.9
% of pts.
8
6
4
2
1.4
0.2
0
HBsAg (+)
Anti-HCV (+)
HBsAg (+) and
Anti-HCV (+)
Blood pressure status in RTx patients (2004)
80
% of pts.
61.2
60
40
28.2
20
9.5
1.1
0
BP <140/90 mmHg
untreated
BP <140/90 mmHg
treated
BP >140/90 mmHg
untreated
BP >140/90 mmHg
treated
45
Cardiovascular diseases in RTx patients (2004)
11.0
Angina pectoris
1.1
Arrythmia
0.9
0.6
Heart failure
0.5
0.4
0.3
0.2
0.2
0.1
0
3
6
9
12
% of pts.
Status of incident RTx patients (2004)
% of pts.
90
80.3
60
30
12.6
3.8
3.3
Returned to HD
Died
0
Functioning graft
46
Allograft
dysfunction
Causes of graft loss in prevalent RTx patients (2004)
Chronic rejection
48.9
Death
38.4
Relapse of the
primary disease
4.7
Acute rejection
4.1
Primary
non-functioning
2.8
Misc.
1.1
0
10
20
30
40
50
% of pts. with graft loss
Causes of death in prevalent RTx patients (2004)
Infection
51.1
Cardiovascular
25.5
Cerebrovascular
accident
6.4
Malignancy
4.3
Pulmonary emboli
2.1
Misc.
10.6
0
20
40
60
% of total deaths
47
Discussion

Evaluation is performed based on the results provided by 25 centers. The number of the RTx
patients on follow up is found as 3395 as of the end of 2004.

The annual number of RTx is increased by 21.7% (n: 665). The rate of cadaver donation is 27.8%.
The rate of RTx patients younger than 15 years old is 4.1%.

Living donations were 85.6% from relatives, 12.9% from spouse and 1.5% from non-relatives.

The frequency of diabetic nephropathy is 3.6% in RTx patients in 2004 and diabetes mellitus is
found as comorbidity in 0.8%. Only 12% of the 25 centers performed pancreas Tx in 2004.
Synchronous kidney and pancreas Tx is performed in 22 patients. The number of the Tx patients
in whom kidney is transplanted first is 10.

The number of the centers performing laparoscopic nephrectomy in living donors is 2 (8%).

Antibody treatment is preferred for induction therapy in 58.3% (n: 388) of the RTx patients, in
2004. In 42.5% of them basiliximab, in 35.3% ATG (horse), in 18.8% daclizumab, and in 3.4%
thymoglobulin (rabbit) is administered.

Increase in the prescribing of the new immunosuppresive agents (mycophenolate mofetil,
tacrolimus, IL-2r monoclonal antibodies) will lead to more selective, efficient and safe treatment
protocols.

Hypertension is observed in 71.8% of the patients as of the end of 2004. Blood pressure is out of
control in 9.5% of treated patients.

The proportions of HBsAg (+) and Anti-HCV (+) patients are 1.4% and 7.5%, respectively, as of
the end of 2004. 29.2% of the centers are performing RTx to HBsAg (+) patients, while 66.7%
performs RTx to anti-HCV (+) patients. These figures are decreased compared to last year.

Due to the mortality analysis of the year 2004, infections are the most common cause of death
(51.1%) and significantly increased compared to last year (34.8%). The most commonly observed
infection is sepsis. Cardiovascular diseases, cerebrovascular accident and malignancy come after
infections, respectively.

Chronic rejection (48.9%) and death (38.4%) are the most common causes of graft loss in 2004;
there found a significant change compared to last year.

Serum creatinin level is <2 mg/dL in 80.3% of the RTx patients while it is >2 mg/dL in 12.6% of
them, in 2004. The proportion of RTx patients who returned to HD is 3.8%, and 19 patients (3.3%)
died.
48
TRENDS IN RENAL TRANSPLANTATION BY YEARS
Number of RTx's performed by years
665
700
600
549
600
475
Count
500
364
400
300
215
382
360
370
193
200
100
0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Distribution of RTx patients due to donor type by years
100
% of pts.
80
60
40
20
0
1991 1993 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Living
Cadaver
Frequency of HBsAg (+) RTx patients by years
4
% of pts.
3
2.9
3.0
3.2
2
1.6
1
0
1997
1998
1999
2004
49
Frequency of Anti-HCV (+) RTx patients by years
30
% of pts.
24.0
23.9
22.5
20
8.1
10
0
1997
1998
1999
2004
% of total deaths
Deaths due to cardiovascular disease in RTx patients
by years
40
30.4
25.5
20
15.7
20.0
13.3
0
1996
1998
2000
2002
2004
% of total deaths
Deaths due to cerebrovascular accident in RTx patients
by years
30
20
10
8.7
6.4
4.1
0
2000
50
11.6
2002
2003
2004
% of total deaths
Deaths due to infections in RTx patients by years
53.3
60
43.3
45.2
44.1
51.5
51.1
40.0
40
34.8
32.6
2002
2003
20
0
1995
1996
1998
1999
2000
2001
2004
% of total deaths
Deaths due to malignancies in RTx patients by years
30
20
10
6.7
6.7
7.2
6.1
1998
2000
2001
2.9
8.6
11.6
4.3
0
1995
1996
2002
2003
2004
Discussion

The number of RTx patients has increased starting from 1995, it is still too low compared to
Europe.

We believe that this number will increase with the help of the efforts being spent by Ministry of
Health in establishing a better organized Tx system.

Through 15 years, there is no significant decrease in the proportion of HBsAg (+) patients while a
significant decrease in the frequency of anti-HCV (+) patients is observed.

Starting from 2000, there observed an increase in the percentage of the deaths due to
cardiovascular diseases.
51
PEDIATRIC NEPHROLOGY *
Primary renal diseases in incident pediatric RRT patients in 2004 ............................ (n:174)
Congenital urologic anomalies (including vesicoureteral reflux) ............................. 25.9%
Primary glomerulonephritis ................................................................................... 20.7%
Neurogenic bladder ................................................................................................ 5.7%
Renal hypoplasia / dysplasia................................................................................... 4.0%
Secondary glomerulonephritis................................................................................. 3.4%
Other diseases ..................................................................................................... 14.3%
* Comments on the results of Pediatric Nephrology, Dialysis and Transplantation are made by
Prof. Dr. Lale SEVER (İstanbul University Cerrahpaşa Faculty of Medicine Departmant of Pediatrics
Division of Clinical Nephrology)
53
Etiology of incident pediatric RRT patients (2004)
Congenital urologic anomalies
25.9
20.7
Primary glomerulonephritis
Neurogenic bladder
5.7
4.0
Renal hypoplasia/dysplasia
Urolithiasis
3.4
Secondary glomerulonephritis
3.4
Misc.
10.9
25.9
Etiology unknown
0
5
10
15
20
25
30
% of pts.
Discussion

Pediatric patient forms are sent to 33 pediatric nephrology centers and 32 of them have
responded.

In 30 of responding centers chronic PD patients, and in 23 of responding centers chronic HD
patients are being followed-up as of the end of 2004. RTx is performed in 13 of pediatric
nephrology centers, in 2004. The number of the centers with RTx patients is 15, as of the end of
2004.

There are 61 pediatric nephrologists in 32 pediatric nephrology centers. There are 28 pediatricians
continuing their education in pediatric nephrology, as of the end of 2004.

There are more than 800 RRT patients in nephrology centers, as of the end of 2004. The
percentages of PD and HD patients are 51% and 13%, respectively. The proportion of RTx
patients is 36%.

Primary renal disease is unknown in 1/4 of the incident RRT patients. Etiologic causes of ESRD
congenital urologic anomalies in 1/4 and primary and secondary glomerulonephritis, each in 1/4.
54
PEDIATRIC HEMODIALYSIS
Prevalent pediatric regular HD patients, as of the end of 2004......................................... 116
Male ..................................................................................................................... 50.0%
Female ................................................................................................................. 50.0%
0-6 years of age...................................................................................................... 0.8%
7-10 years of age.................................................................................................... 9.8%
11-15 years of age................................................................................................ 49.2%
15+ years of age................................................................................................... 40.2%
Frequency of HD sessions in pediatric regular HD patients, as of the end of 2004
Once weekly ........................................................................................................... 3.3%
Twice weekly ........................................................................................................ 12.3%
Three times weekly ............................................................................................... 83.6%
More than three times weekly ................................................................................. 0.8%
Duration of dialysis in pediatric regular HD patients, as of the end of 2004
0-6 months ........................................................................................................... 10.7%
7-12 months ........................................................................................................... 6.6%
13-24 months ....................................................................................................... 25.4%
25-60 months ....................................................................................................... 36.1%
60+ months .......................................................................................................... 21.3%
Types of vascular access in pediatric regular HD patients, as of the end of 2004
AV fistula .............................................................................................................. 77.0%
Catheter ............................................................................................................... 15.6%
AV graft .................................................................................................................. 7.4%
Percentage of pediatric regular HD patients under antihypertensive treatment................... 52.5%
Hepatitis serology in pediatric regular HD patients, as of the end of 2004
HBsAg (+)............................................................................................................... 7.8%
Anti-HCV Ab (+).................................................................................................... 17.6%
55
Age distribution of prevalent pediatric regular
HD patients (2004)
60
49.2
% of pts.
40.2
40
20
9.8
0.8
0
0-6
>6-10
>10-15
>15
Years of age
Types of vascular access in pediatric regular
HD patients (2004)
80
77.0
% of pts.
60
40
15.6
20
7.4
0
AV fistula
Catheter
AV graft
Hepatitis serology in pediatric regular HD patients (2004)
20
17.6
% of pts.
15
10
7.8
5
2.9
0
HBsAg (+)
56
Anti-HCV (+)
HBsAg (+) and
Anti-HCV (+)
Discussion

Only 10% of the regular HD patients are younger than 10 years old. Hemodialysis duration is
longer than 2 years in approximately 60% of HD patients.

AV fistula is being used for vascular access in the vast majority of HD patients (77%).

Proportion of HBsAg (+) pediatric HD patients is 10%, while this figure is 20% for anti-HCV Ab (+)
pediatric HD patients.
57
PEDIATRIC PERITONEAL DIALYSIS
Prevalent pediatric PD patients, as of the end of 2004...................................................... 421
Male ..................................................................................................................... 47.1%
Female ................................................................................................................. 52.9%
0-2 years of age...................................................................................................... 2.4%
3-6 years of age...................................................................................................... 9.9%
7-10 years of age.................................................................................................. 22.4%
11-15 years of age................................................................................................ 33.9%
15+ years of age................................................................................................... 31.5%
Duration of dialysis in pediatric PD patients, as of the end of 2004
0-6 months ........................................................................................................... 12.1%
7-12 months ......................................................................................................... 17.9%
13-24 months ....................................................................................................... 21.2%
25-60 months ....................................................................................................... 30.8%
60+ months .......................................................................................................... 17.9%
PD treatment modality in pediatric PD patients, as of the end of 2004
CAPD ................................................................................................................... 53.4%
APD ..................................................................................................................... 46.6%
Percentage of pediatric PD patients under antihypertensive treatment............................... 63.5%
Hepatitis serology in pediatric PD patients, as of the end of 2004
HBsAg (+)............................................................................................................... 2.7%
Anti-HCV Ab (+)...................................................................................................... 1.9%
Peritonitis in pediatric PD patients in 2004
Percentage of PD patients who experienced peritonitis ......................................... 33.9%
Rate of peritonitis
All PD patients.............................................................................. 1/25.7 months
All CAPD patients ......................................................................... 1/35.5 months
All APD patients ........................................................................... 1/24.3 months
59
PD treatment modality in pediatric PD patients
as of the end of 2004
60
53.4
% of pts.
46.6
40
20
0
CAPD
APD
Age distribution of prevalent pediatric PD patients (2004)
40
33.9
31.5
% of pts.
30
22.4
20
9.9
10
2.4
0
0-2
>2-6
>6-10
>10-15
>15
Years of age
Hepatitis serology in pediatric PD patients (2004)
4
% of pts.
3
2.7
1.9
2
1
0.5
0
HBsAg (+)
60
Anti-HCV (+)
HBsAg (+) and
Anti-HCV (+)
Peritonitis in pediatric PD patients (2004)
80
66.1
% of pts.
60
40
23.5
20
6.1
4.3
2
>2
0
None
1
Number of episodes
Discussion

One-third of the PD patients are younger than 10 years old, as of the end of 2004. PD duration is
more than 2 years in nearly 50% of the patients. PD duration for 18% of the patients is more than
5 years.

The proportion of APD patients is 47%.

The proportions of positivity of hepatitis serology are lower than HD patients; HBsAg (+) 3.2% and
anti-HCV Ab (+) 2.4%.

Average peritonitis rate is found as 1/25.7 patient-months.
61
PEDIATRIC RENAL TRANSPLANTATION
Incident pediatric RTx patients in 2004................................................................................ 59
Male ..................................................................................................................... 50.8%
Female ................................................................................................................. 49.2%
0-6 years of age...................................................................................................... 5.1%
7-10 years of age.................................................................................................... 6.8%
11-15 years of age................................................................................................ 45.8%
15+ years of age................................................................................................... 42.4%
Living donor .......................................................................................................... 50.8%
Cadaver................................................................................................................ 49.2%
Prevalent pediatric RTx patients, as of the end of 2004 .................................................... 279
Duration of waiting of pediatric patients transplanted in 2004
Preemptive Tx ...................................................................................................... 12.7%
<6 months ............................................................................................................ 20.8%
6-12 months ........................................................................................................... 5.5%
13-24 months ....................................................................................................... 25.5%
25-60 months ....................................................................................................... 29.1%
>60 months ............................................................................................................ 7.3%
63
Age distribution of incident pediatric RTx patients (2004)
60
% of pts.
45.8
42.4
40
20
5.1
6.8
0-6
>6-10
0
>10-15
>15
Years of age
Duration of waiting of pediatric patients transplanted (2004)
40
29.1
% of pts.
25.5
20.8
20
12.7
7.3
5.5
0
Preemptive <6 months
Tx
6-12
months
13-24
months
25-60
months
>60
months
Discussion

The number of RTxs performed in 2004 is 59. This figure is similar to the last year. The donors in
half of the RTxs are living related donors.

The duration of waiting on dialysis is more than 2 years in 36% of pediatric RTx patients.
64
Comparative Figures from World and Turkey
65
Figure 1. Worldwide incident rates (per million population)* (USRDS 2004).
* Data represent the most current information available (primarily 2002). Data from Israel,
Japan, Luxembourg, & Taiwan represent dialysis only.
67
Figure 2. European countries/regions contributing to ERA-EDTA Registry
(ERA-EDTA registry newsletter, December 2004).
Registries contributing individual patient data to the ERA-EDTA Registry database
Registries sending aggregated data to be included in the annual report
No registry / no contribution / data not eligible for analysis
68
Figure 3. Incidence of ESRD in some countries in 2003 (USRDS 2004).
Taiw an
United States
Japan
Qatar
Israel
Germany
Belgium
Greece
Spain/Canary Islands
Spain/Valencia
Canada
Spain/Catalonia
Luxembourg
Uruguay
Austria
Korea (Repub of)
Denmark
Chile
Sw eden
Turkey
122
Croatia
New Zealand
Scotland
Netherlands
Poland
Malaysia
Australia
Norw ay
Spain/Basque Country
Finland
Iceland
Latvia
Philippines
Russia
Bangladesh
0
100
200
300
400
Rate per million population
69
Figure 4. Prevalence of ESRD in some countries in 2003 (USRDS 2004).
Japan
Taiw an
United States
Spain/Valencia
Spain/Catalonia
Germany
Canada
Belgium
Greece
Uruguay
Austria
Sw eden
Chile
Denmark
Korea, Republic of
Scotland
Croatia
New Zealand
Israel
Australia
Netherlands
Norw ay
Finland
Qatar
Luxembourg
Iceland
Malaysia
Poland
Turkey
387.5
Latvia
Russia
Bangladesh
Philippines
0
300
600
900
1200
1500
1800
70
Figure 5. Prevalent dialysis patients by modality in some countries in 2003 (USRDS 2004).
In-center HD
Home HD
PD
Bangledesh
Luxembourg
Japan
Chile
Spain/Catalonia
Germany
Uruguay
Russia
Taiw an
Spain/Valencia
Austria
United States
Croatia
Qatar
Greece
Israel
Poland
Belgium
Malaysia
Turkey
Norw ay
Canada
Finland
Korea
Scotland
Denmark
Sw eden
Netherlands
Iceland
Australia
New Zealand
0
20
40
60
80
100
% of pts.
71
Figure 6. Transplant rates in some countries in 2003 (USRDS 2004).
Spain/Catalonia
United States
Spain/Valencia
Norw ay
Austria
Qatar
Netherlands
Sw eden
Canada
Luxembourg
Finland
Denmark
Australia
New Zealand
Belgium
Germany
Scotland
Uruguay
Poland
Israel
Greece
Iceland
Taiw an
Chile
Korea, Republic of
Turkey
8.1
Malaysia
Thailand
Philippines
Russia
Bangladesh
0
20
40
60
80
72
Figure 7. Prevalence of functioning graft in some countries in 2003 (USRDS 2004).
Spain/Catalonia
Norw ay
United States
Spain/Valencia
Sw eden
Austria
Finland
Belgium
Canada
Netherlands
Scotland
Australia
New Zealand
Denmark
Qatar
Iceland
Germany
Chile
Korea, Republic of
Greece
Poland
Uruguay
Croatia
Malaysia
37.9
Turkey
Thailand
Russia
Bangladesh
Philippines
0
200
400
600
73
Table 1. Total RRT expenses in Turkey, France, Germany, Japan and USA
(Erek et al. Nephrology 2004; 9: 33-38).
Total RRT expenses ($)
Treatment modality
Turkey
France
Germany
Japan
U.S.A.
HD
22.759
78.947
44.500
46.000
46.000
CAPD
22.350
23.684
29.000
APD
25.714
RTx (first year)
23.393
RTx (second year)
10.028
29.605
40.000
-
-
-
41.000
-
35.545
50.000
60.000
19.000
27.000
Table 2. Annual growth rate of world population and number of ESRD, HD, PD and RTx
(ESRD patients, 2003, p. 4. Fresenius M.C.)
Approximate annual growth rates
World population
1.2%
ESRD
6%
HD
6%
PD
6%
RTx
5%
Table 3. World population and number of ESRD, HD, PD and RTx patients.
(ESRD patients in 2003, p. 4. Fresenius M.C.)
ESRD patients
1.681.000
HD
1.158.000
PD
141.000
RTx
382.000
World population
6.3 billion
Table 4. Gross mortality rate in Turkey and world. (Nephrol Dial Transplant 2002; 17: 2092).
USA (1999)
Japan (1997)
EU (15 countries)
TURKEY
a
74
Expansion rate of
RRT stock (%)
Gross mortality rate of
RRT patients (%)
9
19.7
7.8
9.3
8.2 (2.3-13)
10.4a
17b
9.4
Death range on RRT in Europe (pmp) is 35-89.
b
HD 18.5%, CAPD 6%, RTx 1.7%.
CENTERS INCLUDED IN THE REGISTRY
75
CENTERS INCLUDED IN THE REGISTRY
in alphabetical order by cities
No
Center
code
City
Name of center
Responsible person
1
2
21EAA
21BJA
ADANA
ADANA
ADANA NUMUNE EĞİTİM VE ARŞ. HST.
ADANA SSK HST.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
21SDA
21DPA
21AKA
21LVA
21MPA
21WLA
21BZA
21DLA
21CNA
21RPA
21UMA
21FSA
21MHA
21PCA
21PUA
21SGA
21MNA
21LHA
21KNA
21EZA
21CBA
21FTA
21EYA
21KHA
21AJA
21KDA
21.Ara
21NKA
21RCA
21NQA
21VNA
21EDA
21GRA
21VWA
21GXA
ADANA
ADANA
ADANA
ADANA
ADANA
ADANA
ADAPAZARI
ADAPAZARI
ADIYAMAN
ADIYAMAN
ADIYAMAN
AFYON
AFYON
AFYON
AFYON
AFYON
AFYON
AFYON
AĞRI
AKSARAY
AMASYA
AMASYA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
38
39
40
41
42
43
44
45
21GYA
21ADA
21AUA
21NHA
21HDA
21AFA
21LNA
21LQA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
ANKARA
BAŞKENT Ü ADANA ARŞ. VE UYG. MERKEZİ PEDİYATRİ
BAŞKENT ÜNİVERSİTESİ ADANA HST.
ÇUKUROVA ÜTF MERKEZİ
ÇUKUROVA ÜTF PEDİYATRİ
FRESENİUS ADANA DİYALİZ MERKEZİ
FRESENİUS GÜNEYDOĞU ADANA DİYALİZ MERKEZİ
ÖZEL SAKARYA NEFROMED DİYALİZ MERKEZİ
SSK ADAPAZARI HST.
ADIYAMAN DEVLET HST.
FRESENİUS ADIYAMAN DİYALİZ MERKEZİ
GÖLBAŞI DEVLET HST.
AFYON DEVLET HST.
AFYON ÖZEL DİYALİZ MERKEZİ
AFYON SKK HST.
BOLVADİN DEVLET HST.
ÇAY DEVLET HST.
DİNAR DEVLET HST.
SANDIKLI DEVLET HST.
AĞRI DEVLET HST.
AKSARAY DEVLET HST.
MERZİFON DEVLET HST.
SABUNCUOĞLU ŞEREFEDDİN DEVLET HST.
ANKARA ATATÜRK EĞİTİM VE ARŞ.HST.
ANKARA NEFROMED GÖRKEM TIP
ANKARA ÜTF İBN-İ SİNA HST.
ANKARA ÜTF PEDİYATRİ
BAŞKENT ÜTF
BAŞKENT ÜTF PEDİYATRİ
BEYPAZARI DEVLET HST.
ÇINAR DİYALİZ MERKEZİ
ÇUBUK DEVLET HST.
DR. SAMİ ULUS ÇOCUK SAĞLIĞI VE HAST. HST.
ECE DİYALİZ
FATİH ÜNİVERSİTESİ HST.
FRESENİUS SAĞLIK HİZMETLERİ YAŞAM DİYALİZ
MERKEZİ
GAMBRO DİYALİZ MERKEZİ
GATA NEFROLOJİ BD
GAZİ ÜTF NEFROLOJİ BD
GAZİ ÜTF PEDİYATRİ
GÜNEŞLİ DİYALİZ MERKEZİ
HACETTEPE ÜTF
HACETTEPE ÜTF PEDİYATRİ
ÖZEL GÖNÜL DİYALİZ MERKEZİ
SIDDIG MOMİN ADAM
ELİF GÜRBÜZ
KASIM YILDIZER
ÜMİT SAATÇİ
DİLEK TORUN
SAİME PAYDAŞ
ALİ ANARAT
SIDDIK MONİN ADAM
PINAR ERGİN
SEDAT AYDIN
BÜLENT KARAMAN
ABDULKADİR DEMİR
46
21YDA
ANKARA
POLATLI DUATEPE DEVLET HST.
47
48
21UXA
21YMA
ANKARA
ANKARA
49
50
51
21BKA
21YCA
21ZKA
ANKARA
ANKARA
ANKARA
S. KOÇHİSAR DEVLET HST.
SAĞLIK BAKANLIĞI DIŞKAPI ÇOCUK HAST. EĞT. VE ARŞ.
HST.
SB. ETLİK İHTİSAS HST.
SEVGİ DİYALİZ MERKEZİ
SİNCAN KOÇ DİYALİZ MERKEZİ
HÜSEYİN ÖZTOP
A.KADİR ERÇOLAK
GÜLDANE ÇETİNKAYA
HASAN SUNGUR
ALİ OSMAN AVCI
ÖZCAN ÇELİK
HÜLYA ÜNAL ŞENCAN
BANU ERKALKAN
YASİN TAŞDEMİR
AHMET AYDOĞDU
ALİ SEZGİN
RUHİ KALAYCIOĞLU
HÜLYA GÜVENCE
ALEV ÖZSARI
MESİHA EKİM
NURHAN ÖZDEMİR
ÜMİT SAATÇİ
SERDAR ŞİRİN
MANSUR KAYATAŞ
RAHMAN SİYAHHAN
AYŞE ÖNER
MELTEM AYLI
TANJU İNANÇ
M.DENİZ AVCI
CANAN VAR
İZZET YAVUZ
ŞÜKRÜ SİNDEL
ABDÜLGAFFAR VURAL
ÇETİN TURGAN
AYŞİN BAKKALOĞLU
MÜZEYYEN IŞIKMAN
GÖNÜL ALTUN
DOĞAN ÇİFTÇİ
CAHİT YALÇIN
AHMET NOYAN
NİLGÜN ÇAKAR
NAZLI KARA
TURGAY BAŞAY
İZZET YAVUZ
AHMET DİRİKOÇ
77
No
Center
code
City
Name of center
Responsible person
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
21AHA
21YKA
21YAA
21KJA
21SHA
21VVA
21HPA
21PVA
21GWA
21UUA
21PKA
21GSA
21VGA
21VHA
21LBA
21PGA
21BRA
21BYA
21AZA
21JUA
21DDA
21JYA
21UWA
21PPA
21YVA
21DHA
21BEA
21RNA
21URA
21KFA
21STA
21GZA
21RDA
21VFA
21ZPA
21KKA
21HJA
21CXA
21FUA
21CZA
21TPA
21CHA
21WWA
21CDA
21GQA
21KTA
21JGA
21VRA
21LCA
21TQA
21FRA
21FQA
21WMA
21MZA
21BNA
21UZA
21CTA
21LRA
21VKA
21DNA
ANKARA
ANTAKYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ANTALYA
ARDAHAN
ARTVİN
ARTVİN
ARTVİN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
AYDIN
BALIKESİR
BALIKESİR
BALIKESİR
BALIKESİR
BALIKESİR
BALIKESİR
BALIKESİR
BALIKESİR
BARTIN
BATMAN
BAYBURT
BİLECİK
BİLECİK
BİNGÖL
BİTLİS
BOLU
BOLU
BOLU
BURDUR
BURDUR
BURDUR
BURSA
BURSA
BURSA
BURSA
TÜRKİYE YÜKSEK İHTİSAS HST.
ANTAKYA EMİR DİYALİZ MERKEZİ
ADALİA DİYALİZ MERKEZİ
AKDENİZ ÜTF PEDİYATRİ
ALANYA DEVLET HST.
ANTALYA BAŞKENT ÜNİVERSİTESİ HST.
ANTALYA DEVLET HST.
ANTALYA DEVLET HST. PEDİYATRİ
CAN DİYALİZ MERKEZİ
ELMALI DEVLET HST.
FİNİKE DEVLET HST.
FRESENİUS ANTALYA TATİL DİYALİZ MERKEZİ
KORKUTELİ DEVLET HST.
MANAVGAT DEVLET HST.
NEFROTALYA NEFROLOJİ MERKEZİ
OLBİA DİYALİZ MERKEZİ
ÖZEL CAN HST.
SSK ANTALYA BÖLGE HST.
AKDENİZ ÜTF HST.
ARDAĞAN DEVLET HST.
ARTVİN DEVLET HST.
HOPA DEVLET HST.
ŞAVŞAT DEVLET HST.
ADNAN MENDERES ÜTF
ADNAN MENDERES ÜTF PEDİYATRİ
AYDIN DEVLET HST.
AYDIN SSK HST.
GÜNEŞ ÖZEL DİYALİZ MERKEZİ
KUŞADASI DEVLET HST.
NAZİLLİ DEVLET HST.
ÖDEMİŞ İKİNCİ BAHAR DİYALİZ MERKEZİ
ÖZEL AYDIN DİYALİZ MERKEZİ
ÖZEL KUŞADASI HST.
SÖKE FEHİME KOCAGÖZ DEVLET HST.
VOLAKA DİYALİZ MERKEZİ
AYVALIK DEVLET HST.
BALIKESİR ATATÜRK DEVLET HST.
BALIKESİR DEVLET HST.
BURHANİYE DEVLET HST.
DR. M. GÜVEN KARAHAN BANDIRMA DEVLET HST.
EDREMİT DEVLET HST.
GÖNEN DEVLET HST.
ÖZEL UMUT HEMODİYALİZ MERKEZİ
BARTIN DEVLET HST.
BATMAN DEVLET HST.
BAYBURT DEVLET HST.
BİLECİK DEVLET HST.
BOZÜYÜK ERTUĞRUL GAZİ DEVLET HST.
BİNGÖL DEVLET HST.
BİTLİS DEVLET HST.
DÜZCE DEVLET HST.
İZZET BAYSAL BOLU DEVLET HST.
ÖZEL NEFRO BOLU HEMODİYALİZ
BUCAK DEVLET HST.
BURDUR DEVLET HST.
GÖLHİSAR DEVLET HST.
BURSA DEVLET HST.
BURSA ULUDAĞ PEDİATRİ
BURSA YÜKSEK İHTİSAS EĞİTİM VE ARŞ. HST.
ÇEKİRGE DEVLET HST.
MEDİHA BORAN
İDRİS EMİR
HALİM YAVUZ
AYŞE GÜR GÜVEN
ERDEM BABACAN
HÜSEYİN ÇELİK
METİN SARIKAYA
78
MÜJDAT YENİCESU
ÖZER YAZICI
ENVER AYAR
METİN SARIKAYA
KEMAL ALADAĞLI
SAİD ÖZER
GÜLTEKİN SÜLEYMANLAR
MUZAFFER SAPAN
YAMAN ERSOY
NEVCAN AKTUĞ
F.FEVZİ ERSOY
NEJAT AKIN
ENVER AKBAŞ
EGEMEN ARIKAN
YAVUZ AKALTUN
HARUN AKAR
FERAH SÖNMEZ
ÜLGER AVCI
KADİR SARI
OSMAN GÖK
BÜLENT ILDIZ
YAŞAR GÜNDOĞDU
GÜNAY ÖNDER
ÜLGER AVCI
YUSUF TUNA
ORHAN YAVUZ
MEVLUT HAMAMCI
O.NURİ TOPAL
SEZGİN ÇETİN
RIZA TOKSOY
ERHAN ÇOLAK
MEHMET TEMELLİ
SEYFULLAH AKKILIÇ
AYHAN AĞAOĞLU
ŞAHİN ÇEÇEN
FADIL EDEBALİ
HÜSEYİN TÜRKER
BAHRİ GÜNDOĞAN
SÜLEYMAN EKİZ
MEHMET YILDIRIM
FİKRET BAŞTIMAR
MUSTAFA EROĞLU
NATAY TUĞRUL
GÜLDEHEN AKBAŞ
İBRAHİM AYDIN
MEHMET BÜLBÜL
TARKAN HAYDAROĞLU
MEHMET USTA
OSMAN DÖNMEZ
ALTAY TÜRKSÖZ
ŞENİZ SEVİNİR
No
Center
code
City
Name of center
Responsible person
112
113
114
115
116
117
118
119
120
121
21JPA
21MCA
21UNA
21WZA
21MSA
21ZRA
21ZSA
21HCA
21ALA
21MBA
BURSA
BURSA
BURSA
BURSA
BURSA
BURSA
BURSA
BURSA
BURSA
ÇANAKKALE
DİAMED ÖZEL DİYALİZ MERKEZİ
İNEGÖL DEVLET HST.
İZNİK DEVLET HST.
KARACABEY DEVLET HST.
MUSTAFA KEMAL PAŞA DEVLET HST.
ÖZEL MUSTAFA KEMALPAŞA DİYALİZ MERKEZİ
R. T. S. ÖZEL DİYALİZ
REN TIP ÖZEL DİYALİZ MERKEZİ
ULUDAĞ ÜTF NEFROLOJİ BD
ÇANAKKALE ÇAN DEVLET HST.
122
123
21EBA
21HUA
ÇANAKKALE
ÇANAKKALE
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
21ZEA
21ECA
21MKA
21FVA
21TRA
21FLA
21LXA
21ULA
21CWA
21CLA
21GTA
21NYA
21BDA
21CJA
21PQA
21FNA
21WAA
21KBA
21KEA
21ZAA
21FFA
21VBA
21FXA
21YHA
21DQA
21CRA
21LSA
21ATA
21DGA
21CFA
21EKA
21BWA
21MDA
21HFA
21AYA
21EEA
21FPA
21WYA
21UVA
21TUA
21YRA
21EGA
21NMA
21NPA
21FWA
21SJA
ÇANAKKALE
ÇANKIRI
ÇORUM
ÇORUM
ÇORUM
ÇORUM
ÇORUM
DENİZLİ
DENİZLİ
DENİZLİ
DENİZLİ
DENİZLİ
DİYARBAKIR
DİYARBAKIR
DİYARBAKIR
DİYARBAKIR
DÜZCE
EDİRNE
EDİRNE
EDİRNE
EDİRNE
EDİRNE
ELAZIĞ
ELAZIĞ
ELAZIĞ
ERZİNCAN
ERZİNCAN
ERZURUM
ERZURUM
ERZURUM
ESKİŞEHİR
ESKİŞEHİR
ESKİŞEHİR
ESKİŞEHİR
ESKİŞEHİR
GAZİANTEP
GAZİANTEP
GAZİANTEP
GAZİANTEP
GAZİANTEP
GAZİANTEP
GİRESUN
GİRESUN
GİRESUN
GÜMÜŞHANE
HAKKARİ
ÇANAKKALE DEVLET HST.
ÇANAKKALE DİYALİZ SAĞLIK YARDIM VE KÜLTÜR VAKFI
DİYALİZ MERKEZİ
ÖZEL ÇANAKKALE MİLLET DİYALİZ MERKEZİ
ÇANKIRI DEVLET HST.
ALACA DEVLET HST.
ÇORUM DEVLET HST.
İSKİLİP DEVLET HST.
SSK ÇORUM HST.
SUNGURLU DEVLET HST.
ÇİVRİL DEVLET HST.
DENİZLİ DEVLET HST.
ERPA ÖZEL SAĞLIK HST.
PAMUKKALE DİYALİZ MERKEZİ
PAMUKKALE ÜTF NEFROLOJİ BD
DİCLE ÜTF
DİYARBAKIR DEVLET HST.
ÖZEL DİYARBAKIR DİYALİZ MERKEZİ
SSK DİYARBAKIR HST.
ÖZEL DÜZCE DİYALİZ MERKEZİ
EDİRNE DEVLET HST.
KEŞAN DEVLET HST.
SELİMİYE DEVLET HST.
TRAKYA ÜTF HST.
UZUNKÖPRÜ DEVLET HST.
ELAZIĞ DEVLET HST.
ELAZIĞ HARPUT DEVLET HST.
FIRAT ÜNİVERSİTESİ FIRAT TIP MERKEZİ
ERZİNCAN DEVLET HST.
ERZİNCAN SSK HST.
ATATÜRK ÜTF
ERZURUM NUMUNE HST.
ERZURUM SSK HST.
ESKİŞEHİR DEVLET HST.
ONYAK HEMODİYALİZ MERKEZİ
RTS YAŞAM DİYALİZ MERKEZİ
SSK ESKİŞEHİR BÖLGE HST.
OSMANGAZİ ÜTF HST.
GAZİANTEP AV. CENGİZ GÖKÇEK DEVLET HST.
GAZİANTEP SSK HST.
GAZİANTEP ÜTF
NİZİP DEVLET HST.
ÖZEL GÜNEYDOĞU HEMODİYALİZ EMRKEZİ
GAZİANTEP ÜTF PEDİYATRİ
GİRESUN DEVLET HST.
GÖREK DEVLET HST.
TİREBOLU DEVLET HST.
GÜMÜŞHANE DEVLET HST.
HAKKARİ DEVLET HST.
UMUR DORA
İ.HALİL SÖZMEN
ÜMİT AYÇİÇEK
ARİF ÜNAL
HÜSEYİN ERENER
HÜSEYİN ERENER
ERDOĞAN GÜL
N.İLAY OKTAY
MUSTAFA GÜLLÜLÜ
SABRİ KÖSE
RAMAZAN DOĞRU
ALİ DEĞİRMENCİ
SEMRA MENGÜ
KAYHAN TANGÖR
AYKUT BAŞER
YASİN CENGİZ
RECEP BURHANOĞLU
ENGİN DEĞİRMENCİ
TİMUR HARZADIN
SEZGİN BAŞKAN
HAYRULLAH SERT
REMZİ DÜNDAR
REMZİ DÜNDAR
NECDET DOĞAN
MURAT ÇOLAKOĞLU
M.EMİN YILMAZ
HASAN TURAN
UĞUR NEDİM YÜCE
ŞENER CİHAN
RAMAZAN ATAGÜN
ASLAN SEFER
FİKRİ ŞENTÜRK
HÜSEYİN AKPINAR
SEDAT ÜSTÜNDAĞ
SAMİ AYDIN
ÖZLEM ERDİNÇ
MEHMET ÇİNKILINÇ
HÜSEYİN ÇELİKER
ADALET ÖZÇİÇEK
ÖZER TERZİOĞLU
ALİ RIZA ODABAŞ
DEMET YİĞİT
SELİM ATAMAN
BÜLENT ÖZGÜR
İNCİ KİPER
MEHMET EROL
NECDET ATALIK
MEHMET SOYDAN
NECATİ BİLGİN
GALİP AKSOY
CELALETTİN USULAN
VERDA ERBEKTE
NECATİ BİLGİN
AYŞE BALAT
ALPER AK
MEHMET ÖZKAN
SELAHATTİN BOZKURT
ZEYNEL BAYRAKTAR
MEDENİ ŞERMET
79
No
Center
code
City
Name of center
Responsible person
170
21FYA
HATAY
ANTAKYA DEVLET HST.
171
172
21MMA
21YEA
HATAY
HATAY
173
174
175
176
177
178
179
180
181
21JZA
21RUA
21KLA
21BPA
21MTA
21KAA
21WQA
21SKA
21VQA
HATAY
HATAY
IĞDIR
ISPARTA
ISPARTA
ISPARTA
ISPARTA
ISPARTA
İÇEL
182
183
184
185
186
187
188
189
190
191
192
21HVA
21AXA
21LAA
21FBA
21YZA
21WSA
21SQA
21MWA
21PSA
21PRA
21FGA
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
BAŞKENT ÜNİVERSİTESİ İSKENDERUN DİYALİZ MERKEZİ
FRESENİUS GÜNEYDOĞU DİYALİZ HİZM. LTD. ŞTİ.
ANTAKYA ŞUBESİ
HATAY İSKENDERUN DEVLET HST.
İSKENDERUN RNC HEMODİYALİZ MERKEZİ
IĞDIR DEVLET HST.
ISPARTA DEVLET HST.
MEDİANT ISPARTA ÖZEL DİYALİZ MERKEZİ
SÜLEYMAN DEMİREL ÜNİVERSİTESİ
SÜLEYMAN DEMİREL ÜTF PEDİYATRİ
YALVAÇ DEVLET HST.
TARSUS DEVLET HST.SAĞLIK EĞİTİM VAKFI DİYALİZ
MERKEZİ
AVCILAR HAYAT HST.
BAŞKENT ÜNİVERSİTESİ İSTANBUL DİYALİZ MERKEZİ
BAYRAKTAR DİYALİZ MERKEZİ
DİAMED A.Ş.
DİAMED ŞİŞLİ DİYALİZ MERKEZİ
DİYALİSANS DİYALİZ VE SAĞLIK HİZMETLERİ A.Ş.
DOĞAN HST.
DR. LÜTFÜ KIRDAR KARTAL EĞİTİM VE ARŞ.HST.
DR. SADİ KAVUK EĞİTİM ARŞ.HST.
DUYGU HST.
FATİH SULTAN MEHMET EĞİTİM VE ARŞ.HST.
İDRİS EMİR
MUSA YÜKSEKGÖNÜL
ZEKİ GÖLOĞLU
MUSA YÜKSEKGÖNÜL
193
194
195
196
197
198
21SNA
21HWA
21BBA
21TGA
21TNA
21AQA
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
FRESENİUS EKOMED DİYALİZ MERKEZİ
FRESENİUS SAĞLIK HİZMETLERİ A. Ş. AVCILAR ŞUBESİ
GATA HAYDARPAŞA EĞİTİM HST.NEFROLOJİ SERVİSİ
GAZİEMİR DİYALİZ MERKEZİ
GÖK HEMODİYALİZ MERKEZİ
HAYDARPAŞA NUMUNE HST.
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
21PTA
21ACA
21DBA
21MQA
21AWA
21AAA
21DVA
21ABA
21PJA
21KYA
21PWA
21LDA
21DMA
21TVA
21NAA
21RLA
21WBA
21WNA
21NWA
21LTA
21LZA
21PEA
21SSA
21NNA
21JBA
21NUA
21BVA
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
IŞIL SAĞLIK HİZMETLERİ-ÇAMLICA MEDİCAM DİYALİZ
İ. Ü.CERRAHPAŞA TIP FAKÜLTESİ DİYALİZ MERKEZİ
İNTERNATİONAL HOSPİTAL
İSTANBUL ÖZEL MERTER VATAN DİYALİZ MERKEZİ
İSTANBUL REN-MED DİYALİZ MERKEZİ
İSTANBUL TF PEDİYATRİ
İSTANBUL Ü CERRAHPAŞA TF PEDİYATRİ
İSTANBUL ÜTF
İSTİNYE DEVLET HST.
KOŞUYOLU ATA HEMODİYALİZ MERKEZİ
KOZYATAĞI DİYALİZ MERKEZİ
KÜÇÜKYALI DİYALİZ MERKEZİ
MARMARA ÜNİVERSİTESİ KADİR HAS
MARMARA ÜTF PEDİYATRİ
MEDİKARE DİYALİZ MERKEZİ
ÖZEL BAHÇELİEVLER DİYALİZ MERKEZİ
ÖZEL ÇAPA HST.
ÖZEL GAZİOSMANPAŞA HST.
ÖZEL KARAMAN DİYALİZ MERKEZİ
ÖZEL KARTAL HST.
ÖZEL MALTEPE ONUR DİYALİZ MERKEZİ
ÖZEL RENİN DİYALİZ MERKEZİ
ÖZEL SİLİVRİ MİLLET HST.
ÖZEL UMUT DİYALİZ MERKEZİ
ÖZEL YAŞAR HST.
ÖZEL ZEYTİNBURNU DAMLA DİYALİZ MERKEZİ
ÖZGÖZÜKARA DİYALİZ MERKEZİ
80
MUSTAFA ALÇIKAYA
MUSTAFA ALÇIKAYA
EMİN AKYILDIZ
TAHSİN MİNKAR
NEŞE TUNÇ
M. TUĞRUL SEZER
FARUK ÖKTEM
ERDOĞAN YAVUZ
MAHMUT AKGÖZ
TANER YÜCETÜRK
METİN ERMAN
KEMAL ÖNEN
YILDIZ BARUT
T.RIFKI EVRENKAYA
NAİL SUAT ÜNVER
MURAT KUYUMCU
MUSTAFA TEKÇE
NURSEL KORKMAZ
MURAT MIHÇIOĞLU
SEHER RAHİME
KEBAPCIOĞLU
ELBİS AHBAP
A. HALİT EROL
SUAT ÜNVER
PINAR ÜRETMEN
PINAR SEYMEN
YILDIZ BARUT
FUNDA TÜRKMEN
MEHMET ALİ TARIM
EKREM EREK
ALİ GÜRÇAY
YALÇIN ÖZBAHAR
NEDİM SARSMAZ
AYDAN ŞİRİN
LALE SEVER
NİLGÜN AYSUNA
YALÇIN ÖZBAHAR
DAVİD ÇUKRAN
FUAD KARSLI
SALİH ÖNCEL
SERHAN TUĞLULAR
HARİKA ALPAY
HAKAN KAPTANOĞLU
MEHMET ŞÜKRÜ SEVER
MEHMET EMİN YILMAZ
MUSTAFA CANBAKAN
ENVER BERBER
MEHMET ALİ ÇOBANOĞLU
BİLGİN ÇAPANOĞLU
ZERRİN EREN
GÜNAY DOĞAN
MUAZZEZ SEZER CAYMAZ
GÜRKAN YURTERİ
AYDOĞAN ÖBEK
ABDULLAH ÖZGÖZÜKARA
No
Center
code
City
Name of center
Responsible person
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
21LYA
21BTA
21YSA
21ANA
21JHA
21ZCA
21BAA
21SMA
21DZA
21ZJA
21MAA
21EFA
21TXA
21BUA
21CEA
21KVA
21NJA
21FZA
21DTA
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İSTANBUL
İZMİR
İZMİR
GÜLÇİN KANTARCI
FATMA KARAKULLUKÇU
245
246
247
248
249
250
251
21JVA
21MGA
21MJA
21BMA
21TYA
21NXA
21CGA
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
252
253
254
255
256
257
258
259
260
261
21SUA
21CKA
21AEA
21KQA
21KSA
21LEA
21NZA
21EHA
21ZMA
21NVA
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
PENDİK DEVLET HST.
RTS TRANSMED DİYALİZ MERKEZİ
S.B HASEKİ EĞİTİM VE ARŞ. HST.
SAĞLIK BAKANLIĞI İSTANBUL EĞİTİM VE ARŞ.HST.
SAĞLIKLI YAŞAM DİYALİZ MERKEZİ
SSK BAKIRKÖY DOĞUMEVİ VE ÇOCUK HST.
SSK GÖZTEPE EĞT. HST.
SSK GÖZTEPE EĞT. VE ARŞ. HASTANESİ PEDİYATRİ
SSK NİŞANTAŞI DİYALİZ MERKEZİ
SULTANBEYLİ DİYALİZ MERKEZİ
ŞAHVA REŞİTPAŞA DİYALİZ MERKEZİ
ŞİŞLİ ETFAL EĞİTİM VE ARŞ.HST.
ŞİŞLİ ETFAL HASTANESİ PEDİYATRİ
TEPEBAŞI VATAN HST.
TÜRK BÖBREK VAKFI AHMET ERMİŞ HST.
TÜRKMED DİYALİZ MERKEZİ
ÜMRANİYE ATA DİYALİZ MERKEZİ
AYTUN ÇIRAY ÖDEMİŞ DEVLET HST.
BAŞKENT ÜNİVERSİTESİ ZÜBEYDE HANIM UYGULAMA VE
ARAŞTIRMA MERKEZİ
BERGAMA DEVLET HST.
ÇEŞME DEVLET HST.
ÇİĞLİ DEVLET HST.
DOKUZ EYLÜL HST.
DOKUZ EYLÜL ÜTF PEDİYATRİ
DR. ERTUĞRUL AKER TİRE DEVLET HST.
DR.BEHÇET UZ ÇOCUK SAĞLIĞI VE HAST. EĞT VE ARŞ.
HST.
EGE GÜNEŞ DİYALİZ MERKEZİ
EGE SAĞLIK VAKFI
EGE ÜTF
EGE ÜTF PEDİYATRİ
EŞREFPAŞA BELEDİYE HST.
FOÇA DEVLET HST.
İKİNCİ YAŞAM DİYALİZ MERKEZİ
İZMİR ATATÜRK EĞİTİM VE ARŞ.HST.
İZMİR CENTRAL HOSPİTAL DİYALİZ MERKEZİ
İZMİR SEVGİ DİYALİZ MERKEZİ
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
21PAA
21WGA
21ZBA
21HLA
21RMA
21ZLA
21NSA
21GUA
21KWA
21ASA
21JJA
21BFA
21UQA
21JWA
21UPA
21UTA
21DEA
21MRA
21SWA
21NTA
21GLA
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
İZMİR
K. MARAŞ
K. MARAŞ
K. MARAŞ
K. MARAŞ
KARABÜK
KARAMAN
İZMİR TEPECİK EĞT. VE ARŞ. HST. PEDİYATRİ
NARLIDERE DİYALİZ MERKEZİ
NASIR DİYALİZ MERKEZİ
ALSANCAK DEVLET HST.
ÖZEL ANKA DİYALİZ MERKEZİ
ÖZEL ÇİĞİLİ UMUT DİYALİZ MERKEZİ
ÖZEL EGE NEFROLOJİ DİYALİZ MERKEZİ
ÖZEL İZMİR HST.
ÖZEL NEFRON KARŞIYAKA DİYALİZ MERKEZİ
SSK TEPECİK EĞİTİM VE ARŞ.HST.ERİŞKİN HEMODİYALİZ
ŞİFA TIP MERKEZİ
TC SAĞLIK BAKANLIĞI İZMİR EĞİTİM VE ARŞ.HST.
TORBALI M. ENVER ŞENERDEM DEVLET HST.
UĞUR DİYALİZ MERKEZİ
URLA DEVLET HST.
AFŞİN DEVLET HST.
DEVLET HST.HÜSNÜ ÖKSÜZ DİYALİZ MERKEZİ
ELBİSTAN DEVLET HST.
FRESENİUS KAHRAMANMARAŞ DİYALİZ MERKEZİ
KARABÜK VATAN HST.
KARAMAN DEVLET HST.
MİNE BESLER
ERALP KUYUCU
GÖNÜL AYDOĞAN
HÜLYA ERGİN
VEDAT ÇELİK
SERHAT AZİZERLİ
TUNCER PAKİZ
ABDÜLKADİR ÜNSAL
GÜL ÖZÇELİK
Ekrem EREK
BİLAL GÖRÇİN
ÇETİN ÖZENER
GÜNDÜZ GÜVEN
BARAN ARAL
YELDA ÇINAR
YILDIRIM KEMAL ÖNER
NEBİL UĞURSAL
ASSLI KILAVUZ
AYKUT SİFİL
SALİH KAVUKÇU
UĞUR GÖNENÇ
MUSTAFA BAK
UFUKÜNER
F. SEVGİ POSTOĞLU
ALİ BAŞÇI
SEVGİ MİR
SERDAR VARER
YILDIRAY ŞİMŞEK
İSMAİL İRFAN YALÇIN
MUSTAFA CİRİT
EROL SALK
ERDAL KARACA
BANU KINAY
NEŞAT AKSU
HASAN TÜRKOĞLU
MUSTAFA CİRİT
ERDAL KARACA
MEHMET SONBAHAR
ASLI KILAVUZ
GÜLAY AŞÇI
ATİLLA ÜZÜM
SONER DUMAN
FATİH AKMAN
TUNCAY SOYAL
HÜSEYİN UZUNER
ERTUĞRUL UĞURTAŞ
A. ÖZLEM DURMUŞ
NİHAT KURTULUŞ
ŞAHİN SAYAN
İSMET ÖNDER IŞIK
HAMDİ EKİCİ
ÖNDER IŞIK
MUSTAFA YETKİN
ÖZCAN SERDOHAN
81
No
Center
code
City
Name of center
Responsible person
283
284
285
286
287
288
21GAA
21CSA
21SXA
21LMA
21SYA
21DRA
KARS
KASTAMONU
KASTAMONU
KASTAMONU
KAYSERİ
KAYSERİ
289
290
291
292
293
294
295
296
297
298
299
300
301
302
21JCA
21ELA
21FKA
21UAA
21WCA
21YTA
21FAA
21CQA
21SZA
21ZHA
21YFA
21JAA
21LJA
21FMA
KAYSERİ
KAYSERİ
KAYSERİ
KAYSERİ
KAYSERİ
KIRIKKALE
KIRIKKALE
KIRKLARELİ
KIRKLARELİ
KIRKLARELİ
KIRKLARELİ
KIRŞEHİR
KİLİS
KOCAELİ
KARS DEVLET HST.
DR. MÜNİF İSLAMOĞLU KASTAMONU DEVLET HST.
İNEBOLU DEVLET HST.
TOSYA DEVLET HST.
ERCİYES DİYALİZ MERKEZİ
ERCİYES ÜNİVERSİTESİ SEMİHA KİBAR ORGAN NAKLİ VE
DİYALİZ MERKEZİ
ERCİYES ÜTF PEDİYATRİ
KAYSERİ DEVLET HST.
KAYSERİ SSK BÖLGE HST.
ÖZEL MELİKGAZİ HST.
RTS AHMET DİYALİZ MERKEZİ
KIRIKKALE DİYALİZ MERKEZİ
KIRIKKALE KADIN DOĞUM VE ÇOCUK HASTALIKLARI HST.
KIRKLARELİ DEVLET HST.
LÜLEBURGAZ DEVLET HST.
ÖZEL DERMAN HST.
ÖZEL ESEN DİYALİZ MERKEZİ
KIRŞEHİR DEVLET HST.
KİLİS DEVLET HST.
ATALİZ DİYALİZ MERKEZİ
303
304
305
306
21DWA
21RYA
21REA
21PYA
KOCAELİ
KOCAELİ
KOCAELİ
KOCAELİ
SÜLEYMAN POYRAZ
ADEM ERSOY
MEHMET ÖZBURAK
MURAT KARAKAŞ
MEHMET DEMİRKAYA
RUHAN DÜŞÜNSEL HAKAN
POYRAZOĞLU
RUHAN DÜŞÜNSEL
SABİHA KARAYA
NEVZAT EKİNCİOĞLU
ŞULE ULUSOY CENGİZ
OKTAY OYMAK
RAFET KOÇ
RAFET KOÇ
SAFİ KARAL
MEHMET GÖRÇİN
ZEKİ PAKSOY
ÖZLEM ESKİOĞLU
İSA TANYERİ
ABDULLAH ÖZAYTÜRK
FERHAN LATİFE
YAVUZ GÖKÇE
MİNE ERKAN
HASAN ÇAKIR
BEYTİ KARACA
HASAN ÇAKIR
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
21GCA
21NFA
21WEA
21VMA
21TAA
21UBA
21RKA
21WKA
21GDA
21ERA
21UCA
21HYA
21TBA
21DCA
21EPA
21ZQA
21MYA
21KXA
21WRA
21DSA
21YLA
21RJA
21DXA
21PMA
21JDA
21FJA
21UEA
21CPA
21HKA
21FHA
21HNA
21PZA
21GBA
KOCAELİ
KOCAELİ
KOCAELİ
KOCAELİ
KOCAELİ
KOCAELİ
KOCAELİ
KOCAELİ
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KONYA
KÜTAHYA
KÜTAHYA
KÜTAHYA
KÜTAHYA
MALATYA
MALATYA
MALATYA
MALATYA
MANİSA
82
DERİNCE DEVLET HST.
GÖLCÜK DEVLET
KARAMÜRSEL DEVLET HST.
KOCAELİ BÜYÜKŞEHİR BELEDİYESİ BELDE A. Ş DİYALİZ
MERKEZİ
KOCAELİ DEVLET HST.
KOCAELİ ÜTF
KOCAELİ ÜTF PEDİYATRİ
M. KAZIM DİNÇ KANDIRA DEVLET HST.
NOVAK GEBZE DİYALİZ MERKEZİ
ÖZEL MARUF DİYALİZ MERKEZİ
R. N. C. RENAL NEFROLOJİ MERKEZİ
RENALİS DİYALİZ MERKEZİ
AKŞEHİR DEVLET HST.
BEYŞEHİR DEVLET HST.
CİHANBEYLİ DEVLET HST.
ÇUMRA DEVLET HST.
FRESENİUS KONYA DİYALİZ MERKEZİ
KONYA EREĞLİ DEVLET HST.
KONYA NUMUNE HST.
ÖZEL İLGİ DİYALİZ MERKEZİ
ÖZEL KONYA DİYALİZ MERKEZİ
ÖZEL ÖLMEZ HEMODİYALİZ MERKEZİ
ÖZEL RTS BEYHEKİM DİYALİZ MERKEZİ
SELÇUK ÜTF
SEYDİŞEHİR DEVLET HST.
SİMAV DEVLET HST.
SSK KONYA BÖLGE HST.
TÜRKİYE SAĞLIK VE TEDAVİ VAKFI KONYA VAKIF HST.
DOÇ. DR. MUSTAFA KALEMLİ TAVŞANLI DEVLET HST.
EVLİYA ÇELEBİ DEVLET HST.
GEDİZ DEVLET HST.
KÜTAHYA DEVLET HST.
FRESENİUS GÜNEYDOĞU HEMODİYALİZ MERKEZİ
İNÖNÜ ÜTF
MALATYA DEVLET HST.
ÖZEL MALATYA HST.
ALAŞEHİR DEVLET HST.
BAYRAM KALAYCI
AHMET YILMAZ
ZELAL BİRCAN
İSMAİL ERMAN
KADİR FARUK DEMİRKOL
FEVZİ AKÇINAR
MUSTAFA AYDIN
HASAN DERMENCİ
İBRAHİM DUMAN
ERSİN KOBANER
HALİL İBARAHİM TORUN
SERAP SEZER
ZEKİ TOMBUL
CENGİZ ÇALIŞIR
HALİL ÖZTÜRK
HÜSEYİN AKA
MELİH ANIL
HASAN HULUSİ SUR
BANU TEK
LÜTFULLAH ALTINTEPE
BEKİR BORAZAN
MUSTAFA ÖZGÜN
MEHMET POLAT
BEYHAN ULUER
LÜTFÜ USLUER
FAHRETTİN DEMİRER
SAADETTİN HARMANDALI
MUSTAFA EKER
MUSTAFA ESENTÜRK
HÜLYA TAŞKAPAN
ERDAL GÖÇMEZ
ERDAL GÖÇMEZ
ZAFER ULAŞAN
No
Center
code
City
Name of center
Responsible person
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
21PNA
21VYA
21RXA
21TCA
21HMA
21PXA
21NLA
21LLA
21TDA
21ZNA
21RWA
21MXA
21WPA
21EJA
21JXA
21YYA
21KMA
21RVA
21VCA
21MEA
21YGA
21KCA
21CMA
21NDA
21VTA
21GEA
21FDA
21ESA
21JSA
21EUA
21WTA
21BXA
21EMA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MANİSA
MERSİN
MERSİN
MERSİN
MERSİN
MERSİN
MERSİN
MERSİN
MUĞLA
MUĞLA
MUĞLA
MUĞLA
MUĞLA
MUĞLA
MUĞLA
MUŞ
NEVŞEHİR
NEVŞEHİR
NEVŞEHİR
NİĞDE
NİĞDE
ORDU
ORDU
CELAL BAYAR ÜTF
CELAL BAYAR ÜTF PEDİYATRİ
DEMİRCİ DEVLET HST.
EGE-SA MANİSA ÖZEL DİYAZLİ MERKEZİ
MANİSA DEVLET HST.
NEFRONEGE NEFROLOJİ MERKEZİ A.Ş.
ÖZEL EGE DİYALİZ MERKEZİ
SALİHLİ DEVLET HST.
SOMA DEVLET HST.
SOMA ÖZEL DİYALİZ MERKEZİ
TURGUTLU DEVLET HST.
ANAMUR
ATA MERSİN DİYALİZ MERKEZİ
MERSİN DEVLET HST.
MERSİN SİLİFKE DEVLET HST.
MERSİN ÜTF PEDİYATRİ
RNC MERSİN DİYALİZ MERKEZİ
SSK TARSUS HST.
75. YIL MİLAS DEVLET HST.
BODRUM DEVLET HST.
FETHİYE DEVLET HST.
MARMARİS DEVLET HST.
MUĞLA DEVLET HST.
ÖZEL FETHİYE DİYALİZ MERKEZİ
ÖZEL YÜCELEN HST.
MUŞ DEVLET HST.
KAPADOKYA DİYALİZ MERKEZİ
NEVŞEHİR DEVLET HST.
ÜRGÜP DEVLET HST.
NİĞDE DEVLET HST.
NİĞDE ÖZEL HEMODİYALİZ MERKEZİ
ORDU DEVLET HST.
ÜNYE DEVLET HST.
SEYHUN KÜRŞAT
373
374
21MUA
21WDA
OSMANGAZİ
OSMANİYE
375
376
377
378
379
380
21JEA
21JTA
21EQA
21ENA
21DYA
21VZA
OSMANİYE
OSMANİYE
RİZE
RİZE
RİZE
SAKARYA
OSMANGAZİ ÜTF PEDİYATRİ
FRESENİUS SAĞLIK HİZMETLERİ A.Ş. OSMANİYE DİYALİZ
MERKEZİ
OSMANİYE DEVLET HST.
OSMANİYE KADİRLİ DEVLET HST.
PAZAR DEVLET HST.
RİZE DEVLET HST.
SSK RİZE BÖLGE HST.
AKYAZI DEVLET HST.
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
21ZGA
21VDA
21CAA
21WFA
21TEA
21EVA
21KRA
21EWA
21BHA
21MVA
21HZA
21LWA
21ETA
21HBA
21TFA
21GFA
SAKARYA
SAKARYA
SAKARYA
SAKARYA
SAKARYA
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SAMSUN
SİİRT
BİLGE HST.
KARASU DEVLET HST.
SAKARYA DEVLET HST.
SAKARYA GEYVE DEVLET HST.
SAKARYA HENDEK DEVLET HST.
BAFRA DEVLET HST.
ÇARŞAMBA DEVLET HST.
HAVZA DEVLET HST.
ONDOKUZ MAYIS ÜTF
ONDOKUZ MAYIS ÜTF PEDİYATRİ
ÖZEL BAFRA DİYALİZ MERKEZİ
ÖZEL SAMSUN DİYALİZ MERKEZİ
SAMSUN DEVLET HST.
SSK SAMSUN BÖLGE HST.
VEZİRKÖPRÜ DEVLET HST.
SİİRT DEVLET HST.
NEJLA TÜRK ÇAKIR
MEHMET ERTEM
PERİHAN TUNCA
SAVAŞ PARMAKSIZOĞLU
İBRAHİM DİLEK
FİKRİ EROL
AHMET AHŞEN
KADİR ÖZKAYA
CUMA ÖZGÜR
NASİP ŞAHİN
MEHMET OLCAY
MEHMET EMİN BAHÇE
MEHMET FIRAT
ALİ DELİBAŞ
NECATİ KIRALP
AHMET SEZER
ÇETİN İNCE
AKİF YILMAZ
BEHZAT GÜLER
TAYYİBE ERKENEZ
NEZİB TUNCAY
TALAT ÖRNEK
ŞAHİN AYDIN
MESUT ÇOLAK
YUSUF KENAN İŞERİ
SEVDAL BİRMAN
SÜLEYMAN EKMEN
TUNCAY GÜRBÜZ
M. ATAKAN CANBULAT
HÜSEYİN SAĞLAM
ÖNDER BURSALI
ADNAN BÜYÜKYAZICI
NURDAN KURAL
TURGAY GÜLER
TURGAY GÜLER
CENGİZ IŞIK
RİNDOL CANKAR
CENGİZ DUYGULU
ALP ÖZATA
BİRCAN YARICI
SEYRAN DOĞAN
AYHAN AYDIN
SAMİ AYHAN
FERİT YAVUZ YILMAZ
SERAP ÇELİK
İSMAİL HAKKI BALİÇ
HASAN ŞEKERCİOĞLU
ALİ BAKAN
EROL CAFER
KUDDUSİ CENGİZ
OZAN ÖZKAYA
HASAN ŞEKERCİOĞLU
MEHMET KUNDAK
KAMURAN KAYNAR
M.AKİF UZUN
YASİN GÜNEŞ
TAHSİN ÇELEPKOLU
83
No
Center
code
City
Name of center
Responsible person
397
398
399
400
401
402
403
404
405
406
407
21JQA
21DJA
21EXA
21GKA
21DUA
21VPA
21VAA
21LPA
21PBA
21RFA
21GHA
SİNOP
SİNOP
SİNOP
SİVAS
SİVAS
SİVAS
SİVAS
ŞANLIURFA
ŞANLIURFA
ŞANLIURFA
ŞANLIURFA
AYANCIK DEVLET HST.
SİNOP ATATÜRK DEVLET HST.
BOYABAT DEVLET HST.
1. İZZETTİN KEYKAVUS DEVLET HST.
CUMHURİYET ÜNİVERSİTESİ
SSK BÖLGE HST.
SUŞEHRİ DEVLET HST.
BİRECİK DEVLET HST.
ÖZEL ŞANLI DİYALİZ MERKEZİ
SSK ŞANLIURFA HST. (BALIKLIGÖL DEVLET HST. )
ŞANLIURFA DEVLET HST.
408
409
410
411
21VLA
21WHA
21PFA
21HXA
TEKİRDAĞ
TEKİRDAĞ
TEKİRDAĞ
TEKİRDAĞ
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
21GMA
21HGA
21CVA
21RHA
21HTA
21RZA
21LFA
21HQA
21DAA
21RGA
21RBA
21PHA
21BCA
21CUA
21USA
21LGA
21CCA
21GNA
21NRA
21WVA
21LUA
21HHA
21MLA
21VEA
21GPA
21GGA
21GJA
21DFA
21CYA
TEKİRDAĞ
TEKİRDAĞ
TOKAT
TOKAT
TOKAT
TOKAT
TOKAT
TOKAT
TRABZON
TRABZON
TRABZON
TRABZON
TRABZON
TRABZON
TUNCELİ
UŞAK
UŞAK
VAN
VAN
VAN
YALOVA
YALOVA
YOZGAT
YOZGAT
YOZGAT
ZONGULDAK
ZONGULDAK
ZONGULDAK
ZONGULDAK
ÇORLU DEVLET HST.
ÖZEL ÇORLU ŞİFA HST.
ŞARKÖY DEVLET HST.
TBV TEKİRDAĞ ŞUBESİ HACI HÜSEYİN TERZİ DİYALİZ
MERKEZİ
TEKİRDAĞ DEVLET HST.
TRAKYA DİYALİZ MERKEZİ
DR. CEVDET AYKAN DEVLET HST.
MED-LİFE ÖZEL DİYALİZ MERKEZİ
NİKSAR DEVLET HST.
TOKAT ERBAA DEVLET HST.
TURHAL DEVLET HST.
ZİLE DEVLET HST.SALİHA KIRGÖZ
FARABİ HST.TRABZON
KARADENİZ TEKNİK ÜTF PEDİYATRİ
ÖZEL KARADENİZ HST.
SÜRMENE DEVLET HST.
TRABZON NUMUNE HST.
TRABZON SSK HST.
TUNCELİ DEVLET HSTANESİ
UMUT HEMODİYALİZ MERKEZİ LTD. ŞTİ.
UŞAK DEVLET HST.
YÜKSEK İHTİSAS HST.
YÜZÜNCÜ YIL ÜTF
YÜZÜNCÜ YIL ÜTF PEDİYATRİ
BAŞKENT ÜNİVERSİTESİ ELMALIK DİYALİZ MERKEZİ
YOLOVA DEVLET HST.
SORGUN DEVLET HST.
YERKÖY DEVLET HST.
YOZGAT DEVLET HST.
KARABÜK DEVLET HST.
KARADENİZ EREĞLİ DEVLET HST.
SSK ZONGULDAK BÖLGE HST.
ZONGULDAK DEVLET HST.
İSKENDER YÜKSEL
KAMİL DURMUŞ
OKHAN ÇETİN
CEVAT TÜRKAY
FÜSUN GÜLTEKİN
MELİH KINCIR
ÖZDAL ÖZTEKİN
AHMET ÖZBAY
ATİLLA ŞENOCAK
YILMAZ ERTÖRER
HİKMET ŞEYHANLIGİL
FEYZULLAH UÇMAK
NECİP ERŞAN
HÜSEYİN ÖZDEMİR
MUZAFFER SEZER
MİNE ÖZÇAKI
84
MEHMET TÜRK
ALAATTİN AKAY
İDRİS MALKAN
MUSTAFA SERT
SELAMİ AYDIN
MEHMET YAMAK
NUSRET AYDOĞAN
ŞÖHRET TUNAY
ŞÜKRÜ ULUSOY
ELİF BAHAT
HAMZA BOZALİOĞLU
DURSUN İNAN
CEVAT TOPAL
TANER ŞEN
MEHMET ÖZDEMİR
SELAHATTİN ÇAKIROĞLU
SELAHATTİN ÇAKIROĞLU
HASAN GÜLER
REHA ERKOÇ
FAHRETTİN ALKAYA
MUSTAFA MEHMETOĞLU
RIZA MERSİN
MURAT YILDIZ
ARİF YÜCEL
ESER MUSTAFA ÖZCAN
NAKİ GÖKHAN TURAN
AHMET BOZKAYA
ŞEHMUS ERTOP

2004 İngilizce (in English)

Transcription

Similar documents

tractor - TracPro

offering replacement parts

2006 (Türkçe-İngilizce)(Turkish/English)

Phase 1 Summary - Withlacoochee Aquatic Restoration

Kata

PVD program - pvd istanbul 2016

precision tools - Industrial and Bearing Supplies

- UCL Discovery

turkısh onlıne journal educatıonal technology

precision tools

Centrifugal Pumps - QUINCIE Oilfield Products

air handlers

Sedra/Smith Microelectronic Circuits 6/E Chapter 3: Diodes

2010 (Türkçe-İngilizce)(Turkish/English)